<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Reprod</journal-id><journal-id journal-id-type="iso-abbrev">Hum. Reprod</journal-id><journal-id journal-id-type="publisher-id">humrep</journal-id><journal-title-group><journal-title>Human Reproduction (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">0268-1161</issn><issn pub-type="epub">1460-2350</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28137754</article-id><article-id pub-id-type="pmc">5850777</article-id><article-id pub-id-type="doi">10.1093/humrep/dew360</article-id><article-id pub-id-type="publisher-id">dew360</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Infertility</subject></subj-group></subj-group></article-categories><title-group><article-title>Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Humaidan</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="dew360af1">1</xref><xref ref-type="aff" rid="dew360af2">2</xref><xref ref-type="corresp" rid="dew360cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Chin</surname><given-names>W.</given-names></name><xref ref-type="aff" rid="dew360af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rogoff</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="dew360af4">4</xref><xref ref-type="author-notes" rid="dew360fn2"></xref></contrib><contrib contrib-type="author"><name><surname>D'Hooghe</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="dew360af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Longobardi</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dew360af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hubbard</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dew360af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schertz</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dew360af4">4</xref></contrib><contrib contrib-type="author"><collab>on behalf of the ESPART Study Investigators</collab><xref ref-type="author-notes" rid="dew360fn1"></xref></contrib></contrib-group><aff id="dew360af1">
<label>1</label>
<addr-line>The Fertility Clinic, Skive Regional Hospital, Skive</addr-line>, <country>Denmark</country></aff><aff id="dew360af2">
<label>2</label>
<addr-line>Faculty of Health</addr-line>, <institution>Aarhus University</institution>, <addr-line>Aarhus</addr-line>, <country>Denmark</country></aff><aff id="dew360af3">
<label>3</label>
<addr-line>Global Biostatistics and Epidemiology, EMD Serono, Billerica, MA</addr-line>, <country>USA, a business of Merck KGaA, Darmstadt, Germany</country></aff><aff id="dew360af4">
<label>4</label>
<addr-line>Global Clinical Development, EMD Serono Research and Development Institute, Billerica, MA</addr-line>, <country>USA, a business of Merck KGaA, Darmstadt, Germany</country></aff><aff id="dew360af5">
<label>5</label>
<addr-line>Global Medical Affairs Fertility, Merck KGaA, Darmstadt</addr-line>, <country>Germany</country></aff><author-notes><corresp id="dew360cor1"><label>*</label>Correspondence address: The Fertility Clinic, Skive Regional Hospital, Faculty of Health, Aarhus University, Skive, Denmark. Tel: +45 23 81 59 91; E-mail: <email>peter.humaidan@midt.rm.dk</email></corresp><fn id="dew360fn2"><label>†</label><p>Former employee of EMD Serono Research and Development Institute, a business of Merck KGaA, Darmstadt, Germany</p></fn><fn id="dew360fn1"><label>‡</label><p>ESPART Study Investigators are listed in the Acknowledgements.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-01-28"><day>28</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>1</month><year>2017</year></pub-date><volume>32</volume><issue>3</issue><fpage>544</fpage><lpage>555</lpage><history><date date-type="received"><day>08</day><month>4</month><year>2016</year></date><date date-type="rev-recd"><day>01</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="dew360.pdf"></self-uri><abstract><title><offsets xml_i="5497" xml_f="5505" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="dew360s1"><title><offsets xml_i="5539" xml_f="5553" txt_i="20" txt_f="34">STUDY QUESTION</offsets></title><p><offsets xml_i="5564" xml_f="5855" txt_i="35" txt_f="326">How does the efficacy and safety of a fixed-ratio combination of recombinant human FSH plus recombinant human LH (follitropin alfa plus lutropin alfa; r-hFSH/r-hLH) compare with that of r-hFSH monotherapy for controlled ovarian stimulation (COS) in patients with poor ovarian response (POR)?</offsets></p></sec><sec id="dew360s2"><title><offsets xml_i="5891" xml_f="5905" txt_i="328" txt_f="342">SUMMARY ANSWER</offsets></title><p><offsets xml_i="5916" xml_f="6067" txt_i="343" txt_f="494">The primary and secondary efficacy endpoints were comparable between treatment groups and the safety profile of both treatment regimens was favourable.</offsets></p></sec><sec id="dew360s3"><title><offsets xml_i="6103" xml_f="6124" txt_i="496" txt_f="517">WHAT IS KNOWN ALREADY</offsets></title><p><offsets xml_i="6135" xml_f="6374" txt_i="518" txt_f="757">Although meta-analyses of clinical trials have suggested some beneficial effect on reproductive outcomes with r-hLH supplementation in patients with POR, the definitions of POR were heterogeneous and limit the comparability across studies.</offsets></p></sec><sec id="dew360s4"><title><offsets xml_i="6410" xml_f="6438" txt_i="759" txt_f="787">STUDY DESIGN, SIZE, DURATION</offsets></title><p><offsets xml_i="6449" xml_f="6742" txt_i="788" txt_f="1081">Phase III, single-blind, active-comparator, randomized, parallel-group clinical trial. Patients were followed for a single ART cycle. A total of 939 women were randomized (1:1) to receive either r-hFSH/r-hLH or r-hFSH. Randomization, stratified by study site and participant age, was conducted</offsets><italic><offsets xml_i="6750" xml_f="6754" txt_i="1081" txt_f="1085"> via</offsets></italic><offsets xml_i="6763" xml_f="6801" txt_i="1085" txt_f="1123"> an interactive voice response system.</offsets></p></sec><sec id="dew360s5" sec-type="methods"><title><offsets xml_i="6856" xml_f="6896" txt_i="1125" txt_f="1165">PARTICIPANTS/MATERIALS, SETTING, METHODS</offsets></title><p><offsets xml_i="6907" xml_f="7350" txt_i="1166" txt_f="1609">Women classified as having POR, based on criteria incorporating the ESHRE Bologna criteria, were down-regulated with a long GnRH agonist protocol and following successful down-regulation were randomized (1:1) to COS with r-hFSH/r-hLH or r-hFSH alone. The primary efficacy endpoint was the number of oocytes retrieved following COS. Safety endpoints included the incidence of adverse events, including ovarian hyperstimulation syndrome (OHSS). </offsets><italic><offsets xml_i="7358" xml_f="7366" txt_i="1609" txt_f="1617">Post hoc</offsets></italic><offsets xml_i="7375" xml_f="7777" txt_i="1617" txt_f="2019"> analyses investigated safety outcomes and correlations between live birth and baseline characteristics (age and number of oocytes retrieved in previous ART treatment cycles or serum anti-Müllerian hormone (AMH)). The significance of the treatment effect was tested by generalized linear models (Poisson regression for counts and logistic regression for binary endpoints) adjusting for age and country.</offsets></p></sec><sec id="dew360s6" sec-type="results"><title><offsets xml_i="7832" xml_f="7867" txt_i="2021" txt_f="2056">MAIN RESULTS AND THE ROLE OF CHANCE</offsets></title><p><offsets xml_i="7878" xml_f="7958" txt_i="2057" txt_f="2137">Of 949 subjects achieving down-regulation, 939 were randomized to r-hFSH/r-hLH (</offsets><italic><offsets xml_i="7966" xml_f="7967" txt_i="2137" txt_f="2138">n</offsets></italic><offsets xml_i="7976" xml_f="7995" txt_i="2138" txt_f="2157"> = 477) or r-hFSH (</offsets><italic><offsets xml_i="8003" xml_f="8004" txt_i="2157" txt_f="2158">n</offsets></italic><offsets xml_i="8013" xml_f="8044" txt_i="2158" txt_f="2189"> = 462) and received treatment.</offsets></p><p><offsets xml_i="8051" xml_f="8678" txt_i="2190" txt_f="2817">Efficacy assessment: In the intention-to-treat (ITT) population, the mean (SD) number of oocytes retrieved (primary endpoint) was 3.3 (2.71) in the r-hFSH/r-hLH group compared with 3.6 (2.82) in the r-hFSH group (between-group difference not statistically significant). The observed difference between treatment groups (r-hFSH/r-hLH and r-hFSH, respectively) for efficacy outcomes decreased over the course of pregnancy (biochemical pregnancy rate: 17.3% versus 23.9%; clinical pregnancy rate: 14.1% versus 16.8%; ongoing pregnancy rate: 11.0% versus 12.4%; and live birth rate: 10.6% versus 11.7%). An interaction (identified </offsets><italic><offsets xml_i="8686" xml_f="8694" txt_i="2817" txt_f="2825">post hoc</offsets></italic><offsets xml_i="8703" xml_f="8988" txt_i="2825" txt_f="3110">) between baseline characteristics related to POR and treatment effect was noted for live birth, with r-hFSH/r-hLH associated with a higher live birth rate for patients with moderate or severe POR, whereas r-hFSH was associated with a higher live birth rate for those with mild POR. A </offsets><italic><offsets xml_i="8996" xml_f="9004" txt_i="3110" txt_f="3118">post hoc</offsets></italic><offsets xml_i="9013" xml_f="9236" txt_i="3118" txt_f="3341"> logistic regression analysis indicated that the incidence of total pregnancy outcome failure was lower in the r-hFSH/r-hLH group (6.7%) compared with the r-hFSH group (12.4%) with an odds ratio of 0.52 (95% CI 0.33, 0.82; </offsets><italic><offsets xml_i="9244" xml_f="9245" txt_i="3341" txt_f="3342">P</offsets></italic><offsets xml_i="9254" xml_f="9264" txt_i="3342" txt_f="3352"> = 0.005).</offsets></p><p><offsets xml_i="9271" xml_f="9574" txt_i="3353" txt_f="3656">Safety assessment: The overall proportion of patients with treatment-emergent adverse events (TEAEs) occurring during or after r-hFSH/r-hLH or r-hFSH use (stimulation or post-stimulation phase) was 19.9% and 26.8%, respectively. There was no consistent pattern of TEAEs associated with either treatment.</offsets></p></sec><sec id="dew360s7"><title><offsets xml_i="9610" xml_f="9642" txt_i="3658" txt_f="3690">LIMITATIONS, REASONS FOR CAUTION</offsets></title><p><offsets xml_i="9653" xml_f="10061" txt_i="3691" txt_f="4099">Despite using inclusion criteria for POR incorporating the ESHRE Bologna criteria, further investigation is needed to determine the impact of the heterogeneity of POR in the Bologna patient population. The observed correlation between baseline clinical characteristics related to POR and live birth rate, as well as the observed differences between groups regarding total pregnancy outcome failure were from </offsets><italic><offsets xml_i="10069" xml_f="10077" txt_i="4099" txt_f="4107">post hoc</offsets></italic><offsets xml_i="10086" xml_f="10381" txt_i="4107" txt_f="4402"> analyses, and the study was not powered for these endpoints. In addition, the attrition rate for pregnancy outcomes in this trial may not reflect general medical practice. Furthermore, as the patient population was predominantly White these results might not be applicable to other ethnicities.</offsets></p></sec><sec id="dew360s8"><title><offsets xml_i="10417" xml_f="10451" txt_i="4404" txt_f="4438">WIDER IMPLICATIONS OF THE FINDINGS</offsets></title><p><offsets xml_i="10462" xml_f="10678" txt_i="4439" txt_f="4655">In the population of women with POR investigated in this study, although the number of oocytes retrieved was similar following stimulation with either a fixed-ratio combination of r-hFSH/r-hLH or r-hFSH monotherapy, </offsets><italic><offsets xml_i="10686" xml_f="10694" txt_i="4655" txt_f="4663">post hoc</offsets></italic><offsets xml_i="10703" xml_f="11068" txt_i="4663" txt_f="5028"> analyses showed that there was a lower rate of total pregnancy outcome failure in patients receiving r-hFSH/r-hLH, in addition to a higher live birth rate in patients with moderate and severe POR. These findings are clinically relevant and require additional investigation. The benefit:risk balance of treatment with either r-hFSH/r-hLH or r-hFSH remains positive.</offsets></p></sec><sec id="dew360s9"><title><offsets xml_i="11104" xml_f="11139" txt_i="5030" txt_f="5065">STUDY FUNDING/COMPETING INTEREST(S)</offsets></title><p><offsets xml_i="11150" xml_f="11597" txt_i="5066" txt_f="5513">This study was funded by Merck KGaA, Darmstadt, Germany. P.H. has received honoraria for lectures and unrestricted research grants from Ferring, Merck KGaA and MSD. D.R. is a former employee of EMD Serono, a business of Merck KGaA, Darmstadt, Germany. J.S., J.H. and W.C. are employees of EMD Serono Research and Development Institute, a business of Merck KGaA, Darmstadt, Germany. T.D.’H. and S.L. are employees of Merck KGaA, Darmstadt, Germany.</offsets></p></sec><sec id="dew360s10"><title><offsets xml_i="11634" xml_f="11659" txt_i="5515" txt_f="5540">TRIAL REGISTRATION NUMBER</offsets></title><p><offsets xml_i="11670" xml_f="11745" txt_i="5541" txt_f="5616">ClinicalTrials.gov identifier: NCT02047227; EudraCT Number: 2013-003817-16.</offsets></p></sec><sec id="dew360s11"><title><offsets xml_i="11782" xml_f="11805" txt_i="5618" txt_f="5641">TRIAL REGISTRATION DATE</offsets></title><p><offsets xml_i="11816" xml_f="11879" txt_i="5642" txt_f="5705">ClinicalTrials.gov: 24 January 2014; EudraCT: 19 December 2013.</offsets></p></sec><sec id="dew360s12"><title><offsets xml_i="11916" xml_f="11949" txt_i="5707" txt_f="5740">DATE OF FIRST PATIENT'S ENROLMENT</offsets></title><p><offsets xml_i="11960" xml_f="11976" txt_i="5741" txt_f="5757">30 January 2014.</offsets></p></sec></abstract><kwd-group><kwd>POR</kwd><kwd>poor ovarian response</kwd><kwd>follitropin alfa</kwd><kwd>lutropin alfa</kwd><kwd>FSH</kwd><kwd>LH</kwd><kwd>Bologna criteria</kwd><kwd>IVF</kwd><kwd>ICSI</kwd><kwd>ART</kwd></kwd-group><counts><page-count count="12"></page-count></counts></article-meta></front><body><sec sec-type="intro" id="dew360s13"><title><offsets xml_i="12340" xml_f="12352" txt_i="5766" txt_f="5778">Introduction</offsets></title><p><offsets xml_i="12363" xml_f="12474" txt_i="5779" txt_f="5890">One in six couples worldwide will experience at least one infertility problem during their reproductive years (</offsets><xref rid="dew360C7" ref-type="bibr"><offsets xml_i="12511" xml_f="12522" txt_i="5890" txt_f="5901">ESHRE, 2014</offsets></xref><offsets xml_i="12529" xml_f="12645" txt_i="5901" txt_f="6017">) and the majority will benefit from ART. Between 5.6% and 35.1% of women will exhibit poor ovarian response (POR) (</offsets><xref rid="dew360C25" ref-type="bibr"><offsets xml_i="12683" xml_f="12693" txt_i="6017" txt_f="6027">Oudendijk </offsets><italic><offsets xml_i="12701" xml_f="12706" txt_i="6027" txt_f="6032">et al</offsets></italic><offsets xml_i="12715" xml_f="12722" txt_i="6032" txt_f="6039">., 2012</offsets></xref><offsets xml_i="12729" xml_f="12935" txt_i="6039" txt_f="6245">). POR does not have a single cause and the population with POR is, therefore, heterogeneous and difficult to concisely characterize, with clinical trials conducted to date using diverse defining criteria (</offsets><xref rid="dew360C9" ref-type="bibr"><offsets xml_i="12972" xml_f="12983" txt_i="6245" txt_f="6256">Ferraretti </offsets><italic><offsets xml_i="12991" xml_f="12996" txt_i="6256" txt_f="6261">et al</offsets></italic><offsets xml_i="13005" xml_f="13012" txt_i="6261" txt_f="6268">., 2011</offsets></xref><offsets xml_i="13019" xml_f="13021" txt_i="6268" txt_f="6270">; </offsets><xref rid="dew360C29" ref-type="bibr"><offsets xml_i="13059" xml_f="13084" txt_i="6270" txt_f="6295">Polyzos and Devroey, 2011</offsets></xref><offsets xml_i="13091" xml_f="13093" txt_i="6295" txt_f="6297">; </offsets><xref rid="dew360C31" ref-type="bibr"><offsets xml_i="13131" xml_f="13156" txt_i="6297" txt_f="6322">Polyzos and Sunkara, 2015</offsets></xref><offsets xml_i="13163" xml_f="13165" txt_i="6322" txt_f="6324">; </offsets><xref rid="dew360C27" ref-type="bibr"><offsets xml_i="13203" xml_f="13217" txt_i="6324" txt_f="6338">Papathanasiou </offsets><italic><offsets xml_i="13225" xml_f="13230" txt_i="6338" txt_f="6343">et al</offsets></italic><offsets xml_i="13239" xml_f="13246" txt_i="6343" txt_f="6350">., 2016</offsets></xref><offsets xml_i="13253" xml_f="13368" txt_i="6350" txt_f="6465">). The most consistent variable affecting ovarian response is age and POR is associated with chronological ageing (</offsets><xref rid="dew360C9" ref-type="bibr"><offsets xml_i="13405" xml_f="13416" txt_i="6465" txt_f="6476">Ferraretti </offsets><italic><offsets xml_i="13424" xml_f="13429" txt_i="6476" txt_f="6481">et al</offsets></italic><offsets xml_i="13438" xml_f="13445" txt_i="6481" txt_f="6488">., 2011</offsets></xref><offsets xml_i="13452" xml_f="13525" txt_i="6488" txt_f="6561">), with subfertility becoming more pronounced after the age of 35 years (</offsets><xref rid="dew360C34" ref-type="bibr"><offsets xml_i="13563" xml_f="13599" txt_i="6561" txt_f="6597">The ESHRE Capri Workshop Group, 2010</offsets></xref><offsets xml_i="13606" xml_f="13870" txt_i="6597" txt_f="6861">). In addition, an age-related decline in response to exogenous gonadotropin stimulation and a reduction in the number of oocytes, oocyte quality, fertilization rate, number of embryos, implantation rate and, ultimately, live birth rate have been well documented (</offsets><xref rid="dew360C24" ref-type="bibr"><offsets xml_i="13908" xml_f="13915" txt_i="6861" txt_f="6868">Nelson </offsets><italic><offsets xml_i="13923" xml_f="13928" txt_i="6868" txt_f="6873">et al</offsets></italic><offsets xml_i="13937" xml_f="13944" txt_i="6873" txt_f="6880">., 2013</offsets></xref><offsets xml_i="13951" xml_f="14188" txt_i="6880" txt_f="7117">). Owing to social changes, more women delay childbearing and this has resulted in a greater number of women in their late thirties and early forties seeking infertility treatment, highlighting the need for studies in patients with POR (</offsets><xref rid="dew360C34" ref-type="bibr"><offsets xml_i="14226" xml_f="14262" txt_i="7117" txt_f="7153">The ESHRE Capri Workshop Group, 2010</offsets></xref><offsets xml_i="14269" xml_f="14271" txt_i="7153" txt_f="7155">; </offsets><xref rid="dew360C15" ref-type="bibr"><offsets xml_i="14309" xml_f="14320" txt_i="7155" txt_f="7166">Kocourkova </offsets><italic><offsets xml_i="14328" xml_f="14333" txt_i="7166" txt_f="7171">et al</offsets></italic><offsets xml_i="14342" xml_f="14349" txt_i="7171" txt_f="7178">., 2014</offsets></xref><offsets xml_i="14356" xml_f="14358" txt_i="7178" txt_f="7180">).</offsets></p><p><offsets xml_i="14365" xml_f="14529" txt_i="7181" txt_f="7345">A systematic review identified 47 randomized controlled trials that used 41 different descriptions for POR, with each definition used by no more than three trials (</offsets><xref rid="dew360C29" ref-type="bibr"><offsets xml_i="14567" xml_f="14592" txt_i="7345" txt_f="7370">Polyzos and Devroey, 2011</offsets></xref><offsets xml_i="14599" xml_f="15139" txt_i="7370" txt_f="7910">). This disparity in the definitions used makes it challenging to compare between, and draw conclusions from, clinical trials investigating women with POR and has meant that, in general, the results of studies and meta-analyses should be interpreted with caution when considering their applicability to clinical practice. To address this lack of consistency, the ESHRE Bologna criteria were developed by consensus in 2011 as an attempt to standardize the definition of POR for use in clinical trials, and to better enable their comparison (</offsets><xref rid="dew360C9" ref-type="bibr"><offsets xml_i="15176" xml_f="15187" txt_i="7910" txt_f="7921">Ferraretti </offsets><italic><offsets xml_i="15195" xml_f="15200" txt_i="7921" txt_f="7926">et al</offsets></italic><offsets xml_i="15209" xml_f="15216" txt_i="7926" txt_f="7933">., 2011</offsets></xref><offsets xml_i="15223" xml_f="15225" txt_i="7933" txt_f="7935">).</offsets></p><p><offsets xml_i="15232" xml_f="15693" txt_i="7936" txt_f="8397">However, following the development of these criteria, no adequately powered, prospective, randomized controlled trials have investigated treatment in this population, and an ideal protocol for controlled ovarian stimulation (COS) in women with POR has yet to be identified. There is, however, some evidence that supplementing recombinant human FSH (r-hFSH) with recombinant human LH (r-hLH) during ART may have beneficial effects on outcomes in women with POR (</offsets><xref rid="dew360C6" ref-type="bibr"><offsets xml_i="15730" xml_f="15736" txt_i="8397" txt_f="8403">Bosch </offsets><italic><offsets xml_i="15744" xml_f="15749" txt_i="8403" txt_f="8408">et al</offsets></italic><offsets xml_i="15758" xml_f="15765" txt_i="8408" txt_f="8415">., 2011</offsets></xref><offsets xml_i="15772" xml_f="15774" txt_i="8415" txt_f="8417">; </offsets><xref rid="dew360C10" ref-type="bibr"><offsets xml_i="15812" xml_f="15817" txt_i="8417" txt_f="8422">Hill </offsets><italic><offsets xml_i="15825" xml_f="15830" txt_i="8422" txt_f="8427">et al</offsets></italic><offsets xml_i="15839" xml_f="15846" txt_i="8427" txt_f="8434">., 2012</offsets></xref><offsets xml_i="15853" xml_f="15855" txt_i="8434" txt_f="8436">; </offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="15893" xml_f="15900" txt_i="8436" txt_f="8443">Lehert </offsets><italic><offsets xml_i="15908" xml_f="15913" txt_i="8443" txt_f="8448">et al</offsets></italic><offsets xml_i="15922" xml_f="15929" txt_i="8448" txt_f="8455">., 2014</offsets></xref><offsets xml_i="15936" xml_f="16131" txt_i="8455" txt_f="8650">). Supplementation with LH may be beneficial owing to increased FSH receptor expression and growth, in addition to improved follicular recruitment and a reduced rate of granulosa cell apoptosis (</offsets><xref rid="dew360C12" ref-type="bibr"><offsets xml_i="16169" xml_f="16182" txt_i="8650" txt_f="8663">Hillier, 2001</offsets></xref><offsets xml_i="16189" xml_f="16191" txt_i="8663" txt_f="8665">; </offsets><xref rid="dew360C32" ref-type="bibr"><offsets xml_i="16229" xml_f="16236" txt_i="8665" txt_f="8672">Ruvolo </offsets><italic><offsets xml_i="16244" xml_f="16249" txt_i="8672" txt_f="8677">et al</offsets></italic><offsets xml_i="16258" xml_f="16265" txt_i="8677" txt_f="8684">., 2007</offsets></xref><offsets xml_i="16272" xml_f="16274" txt_i="8684" txt_f="8686">).</offsets></p><p><offsets xml_i="16281" xml_f="16300" txt_i="8687" txt_f="8706">A meta-analysis by </offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="16338" xml_f="16345" txt_i="8706" txt_f="8713">Lehert </offsets><italic><offsets xml_i="16353" xml_f="16358" txt_i="8713" txt_f="8718">et al</offsets></italic><offsets xml_i="16367" xml_f="16375" txt_i="8718" txt_f="8726">. (2014)</offsets></xref><offsets xml_i="16382" xml_f="16714" txt_i="8726" txt_f="9058">, which included 6443 patients from 40 randomized controlled trials (45 quantitative studies in total), found that there was no difference in the number of oocytes retrieved from women in the overall analysis population who were treated with r-hFSH/r-hLH compared with those treated with r-hFSH alone. However, when women with POR (</offsets><italic><offsets xml_i="16722" xml_f="16723" txt_i="9058" txt_f="9059">n</offsets></italic><offsets xml_i="16732" xml_f="16911" txt_i="9059" txt_f="9238"> = 1077) were considered separately, significantly more oocytes were retrieved with r-hFSH/r-hLH compared with r-hFSH (weighted mean difference +0.75 oocytes; 95% CI 0.14, 1.36) (</offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="16949" xml_f="16956" txt_i="9238" txt_f="9245">Lehert </offsets><italic><offsets xml_i="16964" xml_f="16969" txt_i="9245" txt_f="9250">et al</offsets></italic><offsets xml_i="16978" xml_f="16985" txt_i="9250" txt_f="9257">., 2014</offsets></xref><offsets xml_i="16992" xml_f="17331" txt_i="9257" txt_f="9596">). In addition, significantly higher clinical pregnancy rates were observed with r-hFSH/r-hLH compared with r-hFSH in both the overall population (risk ratio [RR] 1.09; 95% CI 1.01, 1.18) and the subpopulation of women with POR (RR 1.30; 95% CI 1.01, 1.67), with a greater observed difference between treatments observed in the POR group (</offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="17369" xml_f="17376" txt_i="9596" txt_f="9603">Lehert </offsets><italic><offsets xml_i="17384" xml_f="17389" txt_i="9603" txt_f="9608">et al</offsets></italic><offsets xml_i="17398" xml_f="17405" txt_i="9608" txt_f="9615">., 2014</offsets></xref><offsets xml_i="17412" xml_f="17718" txt_i="9615" txt_f="9921">). However, the definitions of POR were heterogeneous among these studies because the criteria were defined by the authors of each study included in the meta-analysis, as all studies preceded the publication of the Bologna criteria. Nonetheless, these study data represented the best available at the time.</offsets></p><p><offsets xml_i="17725" xml_f="18121" txt_i="9922" txt_f="10318">The Efficacy and Safety of Pergoveris in Assisted Reproductive Technology (ESPART) trial was designed to investigate the hypothesis that a fixed-ratio (2:1) combination of r-hFSH/r-hLH was generally safe and superior to r-hFSH alone, in terms of the number of oocytes retrieved, for COS in patients with POR. The POR inclusion criteria used in this trial incorporated the Bologna criteria (Table </offsets><xref ref-type="table" rid="dew360TB2"><offsets xml_i="18160" xml_f="18161" txt_i="10318" txt_f="10319">I</offsets></xref><offsets xml_i="18168" xml_f="18275" txt_i="10319" txt_f="10426">). Fixed-ratio (2:1) combination follitropin alfa/lutropin alfa (r-hFSH 150 IU plus r-hLH 75 IU; Pergoveris</offsets><sup><offsets xml_i="18280" xml_f="18281" txt_i="10426" txt_f="10427">®</offsets></sup><offsets xml_i="18287" xml_f="18789" txt_i="10427" txt_f="10923">; Merck KGaA, Darmstadt, Germany) is indicated for stimulation of follicular development in women with severe LH and FSH deficiency, defined by an endogenous serum LH level &lt;1.2 IU/l. Additionally in some countries, it is indicated for COS in sub-optimal responders, defined as having a previous response to COS characterized by either a small number (&lt;7) of pre-ovulatory follicles or the use of high FSH doses (≥3000 IU per cycle) or advanced (≥35 years) maternal age. Follitropin alfa (GONAL-f</offsets><sup><offsets xml_i="18794" xml_f="18795" txt_i="10923" txt_f="10924">®</offsets></sup><offsets xml_i="18801" xml_f="19139" txt_i="10924" txt_f="11262">; Merck KGaA) is indicated for anovulation in women who have been unresponsive to treatment with clomiphene citrate and for stimulation of multifollicular development in women undergoing superovulation for ART and in association with an LH preparation for stimulation of follicular development in women with severe LH and FSH deficiency.
</offsets><table-wrap id="dew360TB2" orientation="portrait" position="float"><label><offsets xml_i="19213" xml_f="19220" txt_i="11262" txt_f="11269">Table I</offsets></label><caption><p><offsets xml_i="19240" xml_f="19315" txt_i="11269" txt_f="11344">The ESHRE Bologna criteria and the ESPART trial inclusion criteria for POR.</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="19514" xml_f="19543" txt_i="11345" txt_f="11374">2011 ESHRE Bologna criteria, </offsets><xref rid="dew360C9" ref-type="bibr"><offsets xml_i="19580" xml_f="19591" txt_i="11374" txt_f="11385">Ferraretti </offsets><italic><offsets xml_i="19599" xml_f="19604" txt_i="11385" txt_f="11390">et al</offsets></italic><offsets xml_i="19613" xml_f="19621" txt_i="11390" txt_f="11398">. (2011)</offsets></xref></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="19674" xml_f="19703" txt_i="11398" txt_f="11427">ESPART POR inclusion criteria</offsets><xref ref-type="fn" rid="dew360tfn2"><offsets xml_i="19740" xml_f="19741" txt_i="11427" txt_f="11428">*</offsets></xref></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="19805" xml_f="19863" txt_i="11428" txt_f="11486">Advanced maternal age (≥40 years) or any other risk factor</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19896" xml_f="19988" txt_i="11487" txt_f="11576">Advanced maternal age (≥40–&lt;41 years, i.e. patients between their 40th and 41st birthday)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="20030" xml_f="20106" txt_i="11577" txt_f="11653">A previous POR (cycles cancelled or ≤3 oocytes with a conventional protocol)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20139" xml_f="20224" txt_i="11654" txt_f="11739">Previous ART cycle with ≤3 oocytes retrieved with a conventional stimulation protocol</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="20266" xml_f="20330" txt_i="11740" txt_f="11798">An abnormal ORT (AFC &lt;5–7 follicles or AMH &lt;0.5–1.1 ng/ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20363" xml_f="20471" txt_i="11799" txt_f="11907">An abnormal ORT (AMH 0.12–1.3 ng/ml; measured by AMH GEN II ELISA, Beckman Coulter, Inc., High Wycombe, UK) </offsets><xref rid="dew360C17" ref-type="bibr"><offsets xml_i="20509" xml_f="20536" txt_i="11907" txt_f="11934">La Marca and Sunkara (2014)</offsets></xref></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="20585" xml_f="20696" txt_i="11935" txt_f="12046">In the absence of advanced maternal age or abnormal ORT, two previous episodes of POR after maximal stimulation</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20729" xml_f="20811" txt_i="12047" txt_f="12129">Patients with two previous episodes of POR after maximal stimulation were excluded</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn2"><p><sup><offsets xml_i="20882" xml_f="20883" txt_i="12130" txt_f="12131">*</offsets></sup><offsets xml_i="20889" xml_f="20980" txt_i="12131" txt_f="12222">Two out of three POR inclusion criteria needed to be met for inclusion in the ESPART trial.</offsets></p></fn><fn id="dew360tfn3"><p><offsets xml_i="21012" xml_f="21173" txt_i="12223" txt_f="12384">AFC, antral follicle count; ORT, ovarian reserve test; POR, poor ovarian response; ESPART, Efficacy and Safety of Pergoveris in Assisted Reproductive Technology.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec sec-type="methods" id="dew360s14"><title><offsets xml_i="21269" xml_f="21290" txt_i="12387" txt_f="12408">Materials and Methods</offsets></title><p><offsets xml_i="21301" xml_f="21587" txt_i="12409" txt_f="12695">ESPART was a Phase III, randomized, single-blind, parallel-group, active-comparator clinical trial in women undergoing IVF and/or ICSI (ClinicalTrials.gov identifier: NCT02047227; EudraCT Number: 2013-003817-16). A detailed description of the methodology has been published previously (</offsets><xref rid="dew360C14" ref-type="bibr"><offsets xml_i="21625" xml_f="21634" txt_i="12695" txt_f="12704">Humaidan </offsets><italic><offsets xml_i="21642" xml_f="21647" txt_i="12704" txt_f="12709">et al</offsets></italic><offsets xml_i="21656" xml_f="21663" txt_i="12709" txt_f="12716">., 2015</offsets></xref><offsets xml_i="21670" xml_f="22037" txt_i="12716" txt_f="13083">) and is summarized below. The study was performed in accordance with the clinical trial protocol, the ethical principles that have their origin in the Declaration of Helsinki, the International Conference on Harmonization–Good Clinical Practice guidelines and all applicable regulatory requirements. All participants provided written informed consent prior to entry.</offsets></p><sec id="dew360s14a"><title><offsets xml_i="22069" xml_f="22087" txt_i="13084" txt_f="13102">Study participants</offsets></title><p><offsets xml_i="22098" xml_f="22195" txt_i="13103" txt_f="13197">Women were included in ESPART if they were ≥18–&lt;41 years old, had a BMI between 18 and 31 kg/m</offsets><sup><offsets xml_i="22200" xml_f="22201" txt_i="13197" txt_f="13198">2</offsets></sup><offsets xml_i="22207" xml_f="22378" txt_i="13198" txt_f="13369"> (inclusive), were eligible for COS and ART treatment (including ICSI) and had a diagnosis of POR based upon criteria incorporating the 2011 ESHRE Bologna criteria (Table </offsets><xref ref-type="table" rid="dew360TB2"><offsets xml_i="22417" xml_f="22418" txt_i="13369" txt_f="13370">I</offsets></xref><offsets xml_i="22425" xml_f="22428" txt_i="13370" txt_f="13373">) (</offsets><xref rid="dew360C9" ref-type="bibr"><offsets xml_i="22465" xml_f="22476" txt_i="13373" txt_f="13384">Ferraretti </offsets><italic><offsets xml_i="22484" xml_f="22489" txt_i="13384" txt_f="13389">et al</offsets></italic><offsets xml_i="22498" xml_f="22505" txt_i="13389" txt_f="13396">., 2011</offsets></xref><offsets xml_i="22512" xml_f="23172" txt_i="13396" txt_f="14056">). At least two of the POR inclusion criteria had to be met for inclusion in ESPART. The ESHRE Bologna criteria were not utilized as published, rather a stricter interpretation was applied to remove diagnostic subjectivity, reduce patient heterogeneity and exclude patients with the worst reproductive prognosis. In order to achieve this, the trial excluded women with other ‘risk factors for POR’, women aged ≥41 years, and women with at least two previous episodes of POR after maximal stimulation. Furthermore, the upper threshold of serum AMH was increased to 1.3 ng/ml based on evidence that this cutoff level is superior to 1.1 ng/ml for POR prediction (</offsets><xref rid="dew360C8" ref-type="bibr"><offsets xml_i="23209" xml_f="23239" txt_i="14056" txt_f="14086">Ferraretti and Gianaroli, 2014</offsets></xref><offsets xml_i="23246" xml_f="23248" txt_i="14086" txt_f="14088">; </offsets><xref rid="dew360C17" ref-type="bibr"><offsets xml_i="23286" xml_f="23312" txt_i="14088" txt_f="14114">La Marca and Sunkara, 2014</offsets></xref><offsets xml_i="23319" xml_f="23451" txt_i="14114" txt_f="14246">). Additional key exclusion criteria included primary ovarian failure and the use of preimplantation genetic screening or diagnosis.</offsets></p></sec><sec id="dew360s14b"><title><offsets xml_i="23489" xml_f="23523" txt_i="14248" txt_f="14282">Study treatments and interventions</offsets></title><p><offsets xml_i="23534" xml_f="23743" txt_i="14283" txt_f="14492">The trial duration for each patient was a maximum of 365 days, and the trial was conducted between January 2014 and February 2015. Following pituitary down-regulation with daily triptorelin acetate (Decapeptyl</offsets><sup><offsets xml_i="23748" xml_f="23749" txt_i="14492" txt_f="14493">®</offsets></sup><offsets xml_i="23755" xml_f="23995" txt_i="14493" txt_f="14733">; Ferring Pharmaceuticals, Saint-Prex, Switzerland) and a negative pregnancy test, women were randomized 1:1 to undergo COS with either a fixed-ratio combination of r-hFSH 300 IU plus r-hLH 150 IU (follitropin alfa/lutropin alfa; Pergoveris</offsets><sup><offsets xml_i="24000" xml_f="24001" txt_i="14733" txt_f="14734">®</offsets></sup><offsets xml_i="24007" xml_f="24064" txt_i="14734" txt_f="14791">) or r-hFSH 300 IU monotherapy (follitropin alfa; GONAL-f</offsets><sup><offsets xml_i="24069" xml_f="24070" txt_i="14791" txt_f="14792">®</offsets></sup><offsets xml_i="24076" xml_f="24150" txt_i="14792" txt_f="14866">), with the dose fixed for the first 4 days of COS. Women were randomized </offsets><italic><offsets xml_i="24158" xml_f="24161" txt_i="14866" txt_f="14869">via</offsets></italic><offsets xml_i="24170" xml_f="24326" txt_i="14869" txt_f="15022"> an interactive voice response system (Cenduit GmbH, Switzerland), and randomization was stratified by study site and participant age (&lt;35 or ≥35 years).</offsets></p><p><offsets xml_i="24333" xml_f="25374" txt_i="15023" txt_f="16064">The investigator and all site personnel (with the exception of the trial nurse/coordinator and/or pharmacist/pharmacy assistant who informed participants of their treatment) were blinded to treatment allocation throughout the duration of the trial. A special agreement for respecting the blinding procedure was signed by all personnel involved in the trial, and each site documented the procedures used to maintain the blind. In the case of dosage adjustment, the blind was kept intact with generic instructions given to the trial nurse or pharmacist by the investigator, for both trial drugs. The biostatistics team remained blinded to the treatment codes until the database was locked, the Statistical Analysis Plan finalized and the analysis sets agreed. This single-blind design was implemented as the quality and scientific value of the data obtained from an assessor-blind design ensures the highest level of integrity while reducing patients’ treatment burdens resulting from the implementation of a double blind, double-dummy design.</offsets></p><p><offsets xml_i="25381" xml_f="25870" txt_i="16065" txt_f="16554">A long GnRH agonist protocol was used to ensure that the contribution of endogenous LH was minimized, to allow for a fair assessment of the exogenous LH being administered in the group receiving r-hFSH/r-hLH. Triptorelin acetate 0.1 mg was administered daily from cycle day 20–21 after confirmed ovulation in subjects with spontaneous menses or from cycle day 3–4 in anovulatory or oligo-ovulatory subjects with induced menses. Pituitary down-regulation, confirmed by a serum oestradiol (E</offsets><sub><offsets xml_i="25875" xml_f="25876" txt_i="16554" txt_f="16555">2</offsets></sub><offsets xml_i="25882" xml_f="26075" txt_i="16555" txt_f="16748">) level ≤50 pg/ml, was assessed after 14 days of triptorelin acetate treatment. If down-regulation was not confirmed, treatment with triptorelin acetate continued for an additional 7 days. If E</offsets><sub><offsets xml_i="26080" xml_f="26081" txt_i="16748" txt_f="16749">2</offsets></sub><offsets xml_i="26087" xml_f="26336" txt_i="16749" txt_f="16995"> was &gt; 50 pg/ml at Day 21, the subject was excluded from further treatment in the trial. Triptorelin acetate administration was continued in subjects with confirmation of down-regulation until the administration of recombinant hCG (r-hCG; Ovidrel</offsets><sup><offsets xml_i="26341" xml_f="26342" txt_i="16995" txt_f="16996">®</offsets></sup><offsets xml_i="26348" xml_f="26358" txt_i="16996" txt_f="17006">/Ovitrelle</offsets><sup><offsets xml_i="26363" xml_f="26364" txt_i="17006" txt_f="17007">®</offsets></sup><offsets xml_i="26370" xml_f="26441" txt_i="17007" txt_f="17078"> Prefilled Syringe, Merck KGaA) to trigger final follicular maturation.</offsets></p><p><offsets xml_i="26448" xml_f="26980" txt_i="17079" txt_f="17611">Within 4 days after confirmation of down-regulation, either r-hFSH/r-hLH or r-hFSH was administered concurrently with daily triptorelin acetate. Dose adjustments of r-hFSH (either increases or decreases in 75 IU increments, with concomitant automatic adjustment of r-hLH in participants treated with r-hFSH/r-hLH owing to the combined formulation) were allowed after the first 4 days of stimulation, as monitored by study investigators. The maximum allowed daily dose was 450 IU r-hFSH (plus 225 IU r-hLH in the r-hFSH/r-hLH group).</offsets></p><p><offsets xml_i="26987" xml_f="27333" txt_i="17612" txt_f="17958">Once follicle(s) reached a mean diameter of 17–18 mm, a single injection of r-hCG 250 μg was administered to trigger final follicular maturation. Oocyte retrieval was performed 34–38 h after r-hCG administration, and embryo transfer took place according to each centre's standard practice (maximum three embryos), 2–3 days after oocyte retrieval.</offsets></p></sec><sec id="dew360s14c"><title><offsets xml_i="27371" xml_f="27410" txt_i="17960" txt_f="17999">Study objectives and efficacy endpoints</offsets></title><p><offsets xml_i="27421" xml_f="28503" txt_i="18000" txt_f="19082">The primary objective of the ESPART study was to demonstrate superiority of a fixed-ratio combination of r-hFSH/r-hLH compared with r-hFSH in women with POR undergoing COS for IVF/ICSI. The primary efficacy endpoint was the total number of oocytes retrieved per participant. Secondary endpoints included biochemical pregnancy defined as a positive serum hCG determination 15–20 days after r-hCG injection; clinical pregnancy defined as the presence of at least one ultrasound-confirmed gestational sac in the uterus with or without foetal heart activity 35–42 days after r-hCG injection; ongoing pregnancy rate defined as the presence of at least one viable foetus with positive heart activity 10 weeks after embryo transfer; live birth rate; and implantation rate defined as the number of gestational sacs divided by the number of embryos transferred per treatment arm. Additional endpoints included cycle cancellation rate; total dose of r-hFSH administered; and number of metaphase II (MII) oocytes in ICSI patients. The endpoint of ‘total pregnancy outcome failure’ was defined </offsets><italic><offsets xml_i="28511" xml_f="28519" txt_i="19082" txt_f="19090">post hoc</offsets></italic><offsets xml_i="28528" xml_f="28826" txt_i="19090" txt_f="19388"> as a combination of preclinical miscarriage (biochemical pregnancy loss), early spontaneous miscarriage (any spontaneous abortion occurring between clinical and ongoing pregnancy), late spontaneous miscarriage (any spontaneous abortion that occurred after ongoing pregnancy) and ectopic pregnancy.</offsets></p><p><offsets xml_i="28833" xml_f="28886" txt_i="19389" txt_f="19442">After analysis of primary and secondary endpoints, a </offsets><italic><offsets xml_i="28894" xml_f="28902" txt_i="19442" txt_f="19450">post hoc</offsets></italic><offsets xml_i="28911" xml_f="29762" txt_i="19450" txt_f="20295"> analysis was conducted to explore the potential impact of heterogeneity due to variability in baseline clinical characteristics on live birth rates. Live birth rate was selected as it is considered the most important outcome for infertility treatment. This analysis used a baseline severity score (BSC) which was based upon the trial's POR inclusion criteria conditions. The criteria used to define BSC were (i) age ≥40 and (ii) reduced ovarian reserve using stricter cut-offs than those used in the trial, either &lt;2 oocytes retrieved during the most recent previous ART cycle or, if no previous cycle data were available, baseline serum AMH &lt;0.5 ng/ml (measured at screening). The BSC for a subject could take the value 0 (mild) if none of these criteria were met; 1 (moderate) if one criterion was met; or 2 (severe) if two criteria were met.</offsets></p><sec id="dew360s14c_1"><title><offsets xml_i="29796" xml_f="29812" txt_i="20296" txt_f="20312">Safety endpoints</offsets></title><p><offsets xml_i="29823" xml_f="30238" txt_i="20313" txt_f="20728">Safety endpoints in this study were defined as incidence and severity of ovarian hyperstimulation syndrome (OHSS), incidence of adverse events and serious adverse events, assessed in the electronic case report form system during the trial, and local tolerability based on expected injection-site reactions (as included in the label), including injection-site pain, erythema, haematoma, swelling, and/or irritation (</offsets><xref rid="dew360C14" ref-type="bibr"><offsets xml_i="30276" xml_f="30285" txt_i="20728" txt_f="20737">Humaidan </offsets><italic><offsets xml_i="30293" xml_f="30298" txt_i="20737" txt_f="20742">et al</offsets></italic><offsets xml_i="30307" xml_f="30314" txt_i="20742" txt_f="20749">., 2015</offsets></xref><offsets xml_i="30321" xml_f="30323" txt_i="20749" txt_f="20751">; </offsets><xref rid="dew360C22" ref-type="bibr"><offsets xml_i="30361" xml_f="30373" txt_i="20751" txt_f="20763">Merck, 2015a</offsets></xref><offsets xml_i="30380" xml_f="30381" txt_i="20763" txt_f="20764">,</offsets><xref rid="dew360C23" ref-type="bibr"><offsets xml_i="30419" xml_f="30420" txt_i="20764" txt_f="20765">b</offsets></xref><offsets xml_i="30427" xml_f="30798" txt_i="20765" txt_f="21136">). Treatment-emergent adverse events (TEAEs) were defined as adverse events first occurring after the start of down-regulation. OHSS was defined as either early (occurring within 9 days after oocyte retrieval) or late (occurring after Day 10 following oocyte retrieval). Any OHSS leading to hospitalization or medical intervention was defined as a serious adverse event (</offsets><xref rid="dew360C35" ref-type="bibr"><offsets xml_i="30836" xml_f="30854" txt_i="21136" txt_f="21154">Zegers-Hochschild </offsets><italic><offsets xml_i="30862" xml_f="30867" txt_i="21154" txt_f="21159">et al</offsets></italic><offsets xml_i="30876" xml_f="30883" txt_i="21159" txt_f="21166">., 2009</offsets></xref><offsets xml_i="30890" xml_f="31051" txt_i="21166" txt_f="21327">). An additional analysis was conducted to investigate the observed difference between the two groups in TEAEs during the stimulation and post-stimulation phase.</offsets></p></sec></sec><sec id="dew360s14d"><title><offsets xml_i="31095" xml_f="31115" txt_i="21330" txt_f="21350">Statistical analysis</offsets></title><sec id="dew360s14d_1"><title><offsets xml_i="31153" xml_f="31187" txt_i="21351" txt_f="21385">Pre-specified statistical analysis</offsets></title><p><offsets xml_i="31198" xml_f="31421" txt_i="21386" txt_f="21609">The sample size was based on the primary endpoint (total number of oocytes retrieved per participant). Assuming a difference of one retrieved oocyte between r-hFSH/r-hLH and r-hFSH (difference based on the meta-analysis by </offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="31459" xml_f="31466" txt_i="21609" txt_f="21616">Lehert </offsets><italic><offsets xml_i="31474" xml_f="31479" txt_i="21616" txt_f="21621">et al</offsets></italic><offsets xml_i="31488" xml_f="31495" txt_i="21621" txt_f="21628">., 2014</offsets></xref><offsets xml_i="31502" xml_f="31839" txt_i="21628" txt_f="21965">) with a common SD of 4.5, the calculated sample size was 852 randomized participants. Including an estimated 10% dropout rate, the total trial sample size to be enroled was 946 randomized participants. This assumes an overall two-sided significance level of 0.05 and 90% power to detect the stated difference between the treatment arms.</offsets></p><p><offsets xml_i="31846" xml_f="31902" txt_i="21966" txt_f="22022">Five populations were defined for statistical analysis:
</offsets><list list-type="simple"><list-item><p></p></list-item><list-item><p><offsets xml_i="31971" xml_f="32143" txt_i="22023" txt_f="22195">(3) The per-protocol (PP) population, a subset of the ITT population, included all women who did not have any major protocol deviations that were likely to impact efficacy.</offsets></p></list-item><list-item><p><offsets xml_i="32173" xml_f="32342" txt_i="22196" txt_f="22365">(4) The embryo transfer (ET) analysis set, a subset of the ITT population, included all patients who had at least one embryo transferred 2–3 days after oocyte retrieval.</offsets></p></list-item><list-item><p><offsets xml_i="32372" xml_f="32415" txt_i="22366" txt_f="22409">(5) The biochemical pregnancy set (defined </offsets><italic><offsets xml_i="32423" xml_f="32431" txt_i="22409" txt_f="22417">post hoc</offsets></italic><offsets xml_i="32440" xml_f="32537" txt_i="22417" txt_f="22514">) included all randomized patients who had a positive serum hCG 15–20 days after r-hCG injection.</offsets></p></list-item></list></p><p><offsets xml_i="32567" xml_f="32988" txt_i="22516" txt_f="22937">Primary and secondary efficacy endpoints, with the exception of the implantation rate, were analysed in the ITT population. If a patient did not undergo oocyte retrieval, the number of oocytes retrieved was counted as ‘0’ in the ITT population. The primary efficacy endpoint was also analysed in the PP population. The implantation rate was analysed in the ET set. Safety endpoints were assessed in the safety population.</offsets></p><p><offsets xml_i="32995" xml_f="33406" txt_i="22938" txt_f="23346">The primary efficacy endpoint was analysed using a Poisson regression model with terms for treatment group, country and age category (&lt;35 versus ≥35 years). The secondary efficacy endpoints, with the exception of the implantation rate, were analysed using a logistic regression model with the same terms as in the Poisson regression model. The implantation rate was analysed using the chi-squared test. Only </offsets><italic><offsets xml_i="33414" xml_f="33415" txt_i="23346" txt_f="23347">P</offsets></italic><offsets xml_i="33424" xml_f="33556" txt_i="23347" txt_f="23479"> values for the primary endpoint (number of oocytes retrieved) in the ITT population pertain to statistical significance. All other </offsets><italic><offsets xml_i="33564" xml_f="33565" txt_i="23479" txt_f="23480">P</offsets></italic><offsets xml_i="33574" xml_f="33725" txt_i="23480" txt_f="23631"> values are considered nominal as they were not adjusted for multiplicity. Summary descriptive statistics were used for all quantitative variables. SAS</offsets><sup><offsets xml_i="33730" xml_f="33731" txt_i="23631" txt_f="23632">®</offsets></sup><offsets xml_i="33737" xml_f="33795" txt_i="23632" txt_f="23690"> Version 9.2 was used to conduct the statistical analyses.</offsets></p></sec><sec id="dew360s14d_2"><title><offsets xml_i="33835" xml_f="33836" txt_i="23692" txt_f="23693">
</offsets><italic><offsets xml_i="33844" xml_f="33852" txt_i="23693" txt_f="23701">Post hoc</offsets></italic><offsets xml_i="33861" xml_f="33882" txt_i="23701" txt_f="23722"> statistical analyses</offsets></title><p><offsets xml_i="33893" xml_f="34037" txt_i="23723" txt_f="23867">An exploratory analysis was undertaken to investigate the discrepancies between the ESPART study results and those from a recent meta-analysis (</offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="34075" xml_f="34082" txt_i="23867" txt_f="23874">Lehert </offsets><italic><offsets xml_i="34090" xml_f="34095" txt_i="23874" txt_f="23879">et al</offsets></italic><offsets xml_i="34104" xml_f="34111" txt_i="23879" txt_f="23886">., 2014</offsets></xref><offsets xml_i="34118" xml_f="34258" txt_i="23886" txt_f="24026">). The hypothesized discrepancy between the two studies could be attributed to differences in the clinical profile of patients at baseline (</offsets><xref rid="dew360C1" ref-type="bibr"><offsets xml_i="34295" xml_f="34303" txt_i="24026" txt_f="24034">Alviggi </offsets><italic><offsets xml_i="34311" xml_f="34316" txt_i="24034" txt_f="24039">et al</offsets></italic><offsets xml_i="34325" xml_f="34332" txt_i="24039" txt_f="24046">., 2016</offsets></xref><offsets xml_i="34339" xml_f="34364" txt_i="24046" txt_f="24071">). In the meta-analysis (</offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="34402" xml_f="34409" txt_i="24071" txt_f="24078">Lehert </offsets><italic><offsets xml_i="34417" xml_f="34422" txt_i="24078" txt_f="24083">et al</offsets></italic><offsets xml_i="34431" xml_f="34438" txt_i="24083" txt_f="24090">., 2014</offsets></xref><offsets xml_i="34445" xml_f="35154" txt_i="24090" txt_f="24799">), definitions of POR were author-defined and therefore, heterogeneous; all studies preceded the publication of the Bologna criteria. In the ESPART study, inclusion criteria were inspired by and incorporated the ESHRE Bologna criteria, however, these criteria may include patient subgroups with different prognoses. Furthermore, the ESPART pregnancy outcomes suggested a possible benefit of r-hLH supplementation after the establishment of pregnancy (positive hCG). Therefore, the analysis investigated whether r-hLH supplementation may provide a heterogeneous benefit depending on the baseline clinical characteristics, and if r-hLH supplementation may specifically reduce the incidence of pregnancy failure.</offsets></p><p><offsets xml_i="35161" xml_f="35762" txt_i="24800" txt_f="25398">The analysis investigating the potential impact of heterogeneity due to variability in baseline clinical characteristics on live birth rates was conducted in the ITT population. A logistic regression model was used to test the main effect of BSC, the main treatment effect, and the interaction effect between BSC and treatment. All other logistic regression models included terms for treatment group, country and age category (&lt;35 versus ≥35 years). The total pregnancy outcome failure rate was analysed using logistic regression in the ITT population, the ET set and the biochemical pregnancy set.</offsets></p></sec></sec></sec><sec sec-type="results" id="dew360s15"><title><offsets xml_i="35830" xml_f="35837" txt_i="25402" txt_f="25409">Results</offsets></title><p><offsets xml_i="35848" xml_f="35934" txt_i="25410" txt_f="25496">Of 1359 women screened, 1007 women were recruited and started down-regulation (Figure </offsets><xref ref-type="fig" rid="dew360F1"><offsets xml_i="35970" xml_f="35971" txt_i="25496" txt_f="25497">1</offsets></xref><offsets xml_i="35978" xml_f="36451" txt_i="25497" txt_f="25970">). Of these, 949 women achieved down-regulation, and 939 were randomized to undergo COS with r-hFSH/r-hLH or r-hFSH. Following randomization, 462 women started COS with r-hFSH/r-hLH and 477 started with r-hFSH. Randomization occurred at 87 sites in 15 countries. The majority of women who were randomized completed ovarian stimulation (r-hFSH/r-hLH, 91.8%; r-hFSH, 92.2%). Baseline characteristics and demographics were similar for women in the two treatment groups (Table </offsets><xref ref-type="table" rid="dew360TB3"><offsets xml_i="36490" xml_f="36492" txt_i="25970" txt_f="25972">II</offsets></xref><offsets xml_i="36499" xml_f="36557" txt_i="25972" txt_f="26030">). Blinding compliance was maintained at all study sites.
</offsets><table-wrap id="dew360TB3" orientation="portrait" position="float"><label><offsets xml_i="36631" xml_f="36639" txt_i="26030" txt_f="26038">Table II</offsets></label><caption><p><offsets xml_i="36659" xml_f="36801" txt_i="26038" txt_f="26180">Baseline demographic and clinical characteristics of patients randomized to receive either r-hFSH/r-hLH or r-hFSH monotherapy (ITT population)</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char=" " span="1"></col><col align="char" char=" " span="1"></col><col align="char" char=" " span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="37139" xml_f="37153" txt_i="26181" txt_f="26195">r-hFSH/r-hLH (</offsets><italic><offsets xml_i="37161" xml_f="37162" txt_i="26195" txt_f="26196">n</offsets></italic><offsets xml_i="37171" xml_f="37178" txt_i="26196" txt_f="26203"> = 462)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="37224" xml_f="37232" txt_i="26203" txt_f="26211">r-hFSH (</offsets><italic><offsets xml_i="37240" xml_f="37241" txt_i="26211" txt_f="26212">n</offsets></italic><offsets xml_i="37250" xml_f="37257" txt_i="26212" txt_f="26219"> = 477)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="37303" xml_f="37312" txt_i="26219" txt_f="26228">Overall (</offsets><italic><offsets xml_i="37320" xml_f="37321" txt_i="26228" txt_f="26229">n</offsets></italic><offsets xml_i="37330" xml_f="37337" txt_i="26229" txt_f="26236"> = 939)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="37394" xml_f="37416" txt_i="26236" txt_f="26258">Age (years), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37449" xml_f="37459" txt_i="26259" txt_f="26269">38.3 (2.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37492" xml_f="37502" txt_i="26270" txt_f="26280">38.3 (3.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37535" xml_f="37545" txt_i="26281" txt_f="26291">38.3 (3.0)</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="37587" xml_f="37593" txt_i="26292" txt_f="26298">Race, </offsets><italic><offsets xml_i="37601" xml_f="37602" txt_i="26298" txt_f="26299">n</offsets></italic><offsets xml_i="37611" xml_f="37615" txt_i="26299" txt_f="26303"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37657" xml_f="37663" txt_i="26304" txt_f="26310"> White</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37696" xml_f="37706" txt_i="26311" txt_f="26321">439 (95.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37739" xml_f="37749" txt_i="26322" txt_f="26332">454 (95.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37782" xml_f="37792" txt_i="26333" txt_f="26343">893 (95.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37834" xml_f="37857" txt_i="26344" txt_f="26367"> Black/African American</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37890" xml_f="37897" txt_i="26368" txt_f="26375">1 (0.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37930" xml_f="37937" txt_i="26376" txt_f="26383">4 (0.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37970" xml_f="37977" txt_i="26384" txt_f="26391">5 (0.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38019" xml_f="38025" txt_i="26392" txt_f="26398"> Asian</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38058" xml_f="38065" txt_i="26399" txt_f="26406">4 (0.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38098" xml_f="38105" txt_i="26407" txt_f="26414">4 (0.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38138" xml_f="38145" txt_i="26415" txt_f="26422">8 (0.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38187" xml_f="38193" txt_i="26423" txt_f="26429"> Other</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38226" xml_f="38233" txt_i="26430" txt_f="26437">6 (1.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38266" xml_f="38273" txt_i="26438" txt_f="26445">3 (0.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38306" xml_f="38313" txt_i="26446" txt_f="26453">9 (1.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38355" xml_f="38377" txt_i="26454" txt_f="26476"> Not collected at site</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38410" xml_f="38418" txt_i="26477" txt_f="26485">12 (2.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38451" xml_f="38459" txt_i="26486" txt_f="26494">12 (2.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38492" xml_f="38500" txt_i="26495" txt_f="26503">24 (2.6)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38542" xml_f="38551" txt_i="26504" txt_f="26513">BMI (kg/m</offsets><sup><offsets xml_i="38556" xml_f="38557" txt_i="26513" txt_f="26514">2</offsets></sup><offsets xml_i="38563" xml_f="38575" txt_i="26514" txt_f="26526">), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38608" xml_f="38618" txt_i="26527" txt_f="26537">23.4 (3.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38651" xml_f="38661" txt_i="26538" txt_f="26548">23.4 (3.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38694" xml_f="38704" txt_i="26549" txt_f="26559">23.4 (3.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38746" xml_f="38767" txt_i="26560" txt_f="26581">Primary infertility, </offsets><italic><offsets xml_i="38775" xml_f="38776" txt_i="26581" txt_f="26582">n</offsets></italic><offsets xml_i="38785" xml_f="38789" txt_i="26582" txt_f="26586"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38822" xml_f="38832" txt_i="26587" txt_f="26597">300 (64.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38865" xml_f="38875" txt_i="26598" txt_f="26608">319 (66.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38908" xml_f="38918" txt_i="26609" txt_f="26619">619 (65.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38960" xml_f="39002" txt_i="26620" txt_f="26662">Duration of infertility (years), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39035" xml_f="39044" txt_i="26663" txt_f="26672">4.6 (3.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39077" xml_f="39086" txt_i="26673" txt_f="26682">4.4 (3.5)</offsets><sup><xref ref-type="fn" rid="dew360tfn4"><offsets xml_i="39128" xml_f="39129" txt_i="26682" txt_f="26683">*</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="39175" xml_f="39184" txt_i="26684" txt_f="26693">4.5 (3.6)</offsets><sup><xref ref-type="fn" rid="dew360tfn4"><offsets xml_i="39226" xml_f="39227" txt_i="26693" txt_f="26694">*</offsets></xref></sup></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="39282" xml_f="39303" txt_i="26695" txt_f="26716">Type of infertility, </offsets><italic><offsets xml_i="39311" xml_f="39312" txt_i="26716" txt_f="26717">n</offsets></italic><offsets xml_i="39321" xml_f="39325" txt_i="26717" txt_f="26721"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="39367" xml_f="39383" txt_i="26722" txt_f="26738"> Female and male</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39416" xml_f="39426" txt_i="26739" txt_f="26749">186 (40.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39459" xml_f="39469" txt_i="26750" txt_f="26760">185 (38.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39502" xml_f="39512" txt_i="26761" txt_f="26771">371 (39.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="39554" xml_f="39566" txt_i="26772" txt_f="26784"> Female only</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39599" xml_f="39609" txt_i="26785" txt_f="26795">276 (59.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39642" xml_f="39652" txt_i="26796" txt_f="26806">292 (61.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39685" xml_f="39695" txt_i="26807" txt_f="26817">568 (60.5)</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="39737" xml_f="39766" txt_i="26818" txt_f="26847">Cause of female infertility, </offsets><italic><offsets xml_i="39774" xml_f="39775" txt_i="26847" txt_f="26848">n</offsets></italic><offsets xml_i="39784" xml_f="39788" txt_i="26848" txt_f="26852"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="39830" xml_f="39843" txt_i="26853" txt_f="26866"> Tubal factor</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39876" xml_f="39885" txt_i="26867" txt_f="26876">68 (14.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39918" xml_f="39927" txt_i="26877" txt_f="26886">85 (17.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39960" xml_f="39970" txt_i="26887" txt_f="26897">153 (16.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40012" xml_f="40042" txt_i="26898" txt_f="26928"> Endometriosis (Grade I or II)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40075" xml_f="40084" txt_i="26929" txt_f="26938">46 (10.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40117" xml_f="40125" txt_i="26939" txt_f="26947">41 (8.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40158" xml_f="40166" txt_i="26948" txt_f="26956">87 (9.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40208" xml_f="40228" txt_i="26957" txt_f="26977"> Ovulary dysfunction</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40261" xml_f="40270" txt_i="26978" txt_f="26987">55 (11.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40303" xml_f="40312" txt_i="26988" txt_f="26997">67 (14.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40345" xml_f="40355" txt_i="26998" txt_f="27008">122 (13.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40397" xml_f="40416" txt_i="27009" txt_f="27028">  Oligo-amenorrhoea</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40449" xml_f="40457" txt_i="27029" txt_f="27037">11 (2.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40490" xml_f="40498" txt_i="27038" txt_f="27046">15 (3.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40531" xml_f="40539" txt_i="27047" txt_f="27055">26 (2.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40581" xml_f="40602" txt_i="27056" txt_f="27077">  Primary amenorrhoea</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40635" xml_f="40636" txt_i="27078" txt_f="27079">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40669" xml_f="40670" txt_i="27080" txt_f="27081">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40703" xml_f="40704" txt_i="27082" txt_f="27083">0</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40746" xml_f="40769" txt_i="27084" txt_f="27107">  Secondary amenorrhoea</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40802" xml_f="40809" txt_i="27108" txt_f="27115">1 (0.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40842" xml_f="40849" txt_i="27116" txt_f="27123">1 (0.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40882" xml_f="40889" txt_i="27124" txt_f="27131">2 (0.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40931" xml_f="40955" txt_i="27132" txt_f="27156">  Menstrual irregularity</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40988" xml_f="40996" txt_i="27157" txt_f="27165">21 (4.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41029" xml_f="41037" txt_i="27166" txt_f="27174">33 (6.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41070" xml_f="41078" txt_i="27175" txt_f="27183">54 (5.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41120" xml_f="41163" txt_i="27184" txt_f="27227">  Normal menstrual cycle with luteal defect</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41196" xml_f="41204" txt_i="27228" txt_f="27236">22 (4.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41237" xml_f="41245" txt_i="27237" txt_f="27245">18 (3.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41278" xml_f="41286" txt_i="27246" txt_f="27254">40 (4.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41328" xml_f="41335" txt_i="27255" txt_f="27262">  Other</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41368" xml_f="41378" txt_i="27263" txt_f="27273">336 (72.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41411" xml_f="41421" txt_i="27274" txt_f="27284">330 (69.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41454" xml_f="41464" txt_i="27285" txt_f="27295">666 (70.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41506" xml_f="41554" txt_i="27296" txt_f="27344">At least one ART cycle with ≤3 oocytes retrieved</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41587" xml_f="41597" txt_i="27345" txt_f="27355">379 (82.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41630" xml_f="41640" txt_i="27356" txt_f="27366">402 (84.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41673" xml_f="41683" txt_i="27367" txt_f="27377">781 (83.2)</offsets></td></tr><tr><td colspan="4" rowspan="1"><offsets xml_i="41725" xml_f="41757" txt_i="27378" txt_f="27410">Number of previous live births, </offsets><italic><offsets xml_i="41765" xml_f="41767" txt_i="27410" txt_f="27412">n </offsets></italic><offsets xml_i="41776" xml_f="41779" txt_i="27412" txt_f="27415">(%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41821" xml_f="41823" txt_i="27416" txt_f="27418"> 0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41856" xml_f="41866" txt_i="27419" txt_f="27429">375 (81.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41899" xml_f="41909" txt_i="27430" txt_f="27440">384 (80.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41942" xml_f="41952" txt_i="27441" txt_f="27451">759 (80.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41994" xml_f="41996" txt_i="27452" txt_f="27454"> 1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42029" xml_f="42038" txt_i="27455" txt_f="27464">80 (17.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42071" xml_f="42080" txt_i="27465" txt_f="27474">84 (17.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42113" xml_f="42123" txt_i="27475" txt_f="27485">164 (17.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="42165" xml_f="42167" txt_i="27486" txt_f="27488"> 2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42200" xml_f="42207" txt_i="27489" txt_f="27496">7 (1.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42240" xml_f="42247" txt_i="27497" txt_f="27504">7 (1.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42280" xml_f="42288" txt_i="27505" txt_f="27513">14 (1.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="42330" xml_f="42332" txt_i="27514" txt_f="27516"> 3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42365" xml_f="42366" txt_i="27517" txt_f="27518">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42399" xml_f="42406" txt_i="27519" txt_f="27526">2 (0.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42439" xml_f="42446" txt_i="27527" txt_f="27534">2 (0.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="42488" xml_f="42520" txt_i="27535" txt_f="27567">Antral follicle count, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42553" xml_f="42562" txt_i="27568" txt_f="27577">4.9 (2.3)</offsets><sup><xref ref-type="fn" rid="dew360tfn5"><offsets xml_i="42604" xml_f="42605" txt_i="27577" txt_f="27578">†</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="42651" xml_f="42660" txt_i="27579" txt_f="27588">4.8 (2.2)</offsets><sup><xref ref-type="fn" rid="dew360tfn6"><offsets xml_i="42702" xml_f="42703" txt_i="27588" txt_f="27589">‡</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="42749" xml_f="42758" txt_i="27590" txt_f="27599">4.8 (2.2)</offsets><sup><xref ref-type="fn" rid="dew360tfn7"><offsets xml_i="42800" xml_f="42801" txt_i="27599" txt_f="27600">§</offsets></xref></sup></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="42856" xml_f="42910" txt_i="27601" txt_f="27652">At least one ovarian cyst with a mean size &gt;25 mm, </offsets><italic><offsets xml_i="42918" xml_f="42919" txt_i="27652" txt_f="27653">n</offsets></italic><offsets xml_i="42928" xml_f="42932" txt_i="27653" txt_f="27657"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42965" xml_f="42972" txt_i="27658" txt_f="27665">4 (0.9)</offsets><sup><xref ref-type="fn" rid="dew360tfn8"><offsets xml_i="43014" xml_f="43016" txt_i="27665" txt_f="27667">||</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="43062" xml_f="43069" txt_i="27668" txt_f="27675">1 (0.2)</offsets><sup><xref ref-type="fn" rid="dew360tfn8"><offsets xml_i="43111" xml_f="43113" txt_i="27675" txt_f="27677">||</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="43159" xml_f="43166" txt_i="27678" txt_f="27685">5 (0.5)</offsets><sup><xref ref-type="fn" rid="dew360tfn6"><offsets xml_i="43208" xml_f="43209" txt_i="27685" txt_f="27686">‡</offsets></xref></sup></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="43264" xml_f="43292" txt_i="27687" txt_f="27715">AMH level (ng/ml), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43325" xml_f="43337" txt_i="27716" txt_f="27728">0.58 (0.498)</offsets><sup><xref ref-type="fn" rid="dew360tfn9"><offsets xml_i="43379" xml_f="43380" txt_i="27728" txt_f="27729">¶</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="43426" xml_f="43438" txt_i="27730" txt_f="27742">0.60 (0.485)</offsets><xref ref-type="fn" rid="dew360tfn4"><offsets xml_i="43475" xml_f="43476" txt_i="27742" txt_f="27743">*</offsets></xref></td><td rowspan="1" colspan="1"><offsets xml_i="43516" xml_f="43528" txt_i="27744" txt_f="27756">0.59 (0.491)</offsets><sup><xref ref-type="fn" rid="dew360tfn6"><offsets xml_i="43570" xml_f="43571" txt_i="27756" txt_f="27757">‡</offsets></xref></sup></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="43626" xml_f="43668" txt_i="27758" txt_f="27800">Met all three inclusion criteria for POR, </offsets><italic><offsets xml_i="43676" xml_f="43677" txt_i="27800" txt_f="27801">n</offsets></italic><offsets xml_i="43686" xml_f="43690" txt_i="27801" txt_f="27805"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43723" xml_f="43733" txt_i="27806" txt_f="27816">127 (27.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43766" xml_f="43776" txt_i="27817" txt_f="27827">133 (27.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43809" xml_f="43819" txt_i="27828" txt_f="27838">260 (27.7)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn4"><p><sup><offsets xml_i="43890" xml_f="43891" txt_i="27839" txt_f="27840">*</offsets></sup><offsets xml_i="43897" xml_f="43927" txt_i="27840" txt_f="27870">Data missing for two patients.</offsets></p></fn><fn id="dew360tfn5"><p><sup><offsets xml_i="43964" xml_f="43965" txt_i="27871" txt_f="27872">†</offsets></sup><offsets xml_i="43971" xml_f="44003" txt_i="27872" txt_f="27904">Data missing for seven patients.</offsets></p></fn><fn id="dew360tfn6"><p><sup><offsets xml_i="44040" xml_f="44041" txt_i="27905" txt_f="27906">‡</offsets></sup><offsets xml_i="44047" xml_f="44077" txt_i="27906" txt_f="27936">Data missing for six patients.</offsets></p></fn><fn id="dew360tfn7"><p><sup><offsets xml_i="44114" xml_f="44115" txt_i="27937" txt_f="27938">§</offsets></sup><offsets xml_i="44121" xml_f="44150" txt_i="27938" txt_f="27967">Data missing for 13 patients.</offsets></p></fn><fn id="dew360tfn8"><p><sup><offsets xml_i="44187" xml_f="44189" txt_i="27968" txt_f="27970">||</offsets></sup><offsets xml_i="44195" xml_f="44227" txt_i="27970" txt_f="28002">Data missing for three patients.</offsets></p></fn><fn id="dew360tfn9"><p><sup><offsets xml_i="44264" xml_f="44265" txt_i="28003" txt_f="28004">¶</offsets></sup><offsets xml_i="44271" xml_f="44302" txt_i="28004" txt_f="28035">Data missing for four patients.</offsets></p></fn><fn id="dew360fn106"><p><offsets xml_i="44335" xml_f="44447" txt_i="28036" txt_f="28148">ITT, intention-to-treat; POR, poor ovarian response; r-hFSH, recombinant human FSH; r-hLH, recombinant human LH.</offsets></p></fn></table-wrap-foot></table-wrap></p><fig id="dew360F1" orientation="portrait" position="float"><label><offsets xml_i="44557" xml_f="44565" txt_i="28150" txt_f="28158">Figure 1</offsets></label><caption><p><offsets xml_i="44585" xml_f="44768" txt_i="28158" txt_f="28341">Patient disposition during the ESPART study. ESPART, Efficacy and Safety of Pergoveris in Assisted Reproductive Technology; r-hFSH, recombinant human FSH; r-hLH, recombinant human LH.</offsets></p></caption><graphic xlink:href="dew360f01"></graphic></fig><sec id="dew360s15a"><title><offsets xml_i="44858" xml_f="44877" txt_i="28342" txt_f="28361">Efficacy evaluation</offsets></title><p><offsets xml_i="44888" xml_f="45023" txt_i="28362" txt_f="28497">The mean (SD) number of oocytes retrieved in the r-hFSH/r-hLH group was 3.3 (2.71) compared with 3.6 (2.82) in the r-hFSH group (Table </offsets><xref ref-type="table" rid="dew360TB4"><offsets xml_i="45062" xml_f="45065" txt_i="28497" txt_f="28500">III</offsets></xref><offsets xml_i="45072" xml_f="45198" txt_i="28500" txt_f="28623">). Using the Poisson regression model with terms for treatment group, country and age category (&lt;35 versus ≥35 years), the </offsets><italic><offsets xml_i="45206" xml_f="45207" txt_i="28623" txt_f="28624">P</offsets></italic><offsets xml_i="45216" xml_f="45298" txt_i="28624" txt_f="28706">-value for the treatment effect was 0.054 without adjustment for over-dispersion (</offsets><italic><offsets xml_i="45306" xml_f="45307" txt_i="28706" txt_f="28707">P</offsets></italic><offsets xml_i="45316" xml_f="45421" txt_i="28707" txt_f="28812"> = 0.182 with adjustment for over-dispersion). A similar result was obtained in the PP population (Table </offsets><xref ref-type="table" rid="dew360TB4"><offsets xml_i="45460" xml_f="45463" txt_i="28812" txt_f="28815">III</offsets></xref><offsets xml_i="45470" xml_f="45798" txt_i="28815" txt_f="29143">). A small proportion of patients categorized as having POR through fulfilment of the inclusion criteria did not display the expected poor response, with 33 patients having at least 10 oocytes retrieved (12 patients receiving r-hFSH/r-hLH and 21 receiving r-hFSH). The baseline characteristics of these 33 patients are shown in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="45849" xml_f="45871" txt_i="29143" txt_f="29165">Supplementary Table SI</offsets></xref><offsets xml_i="45878" xml_f="45880" txt_i="29165" txt_f="29167">.
</offsets><table-wrap id="dew360TB4" orientation="portrait" position="float"><label><offsets xml_i="45954" xml_f="45963" txt_i="29167" txt_f="29176">Table III</offsets></label><caption><p><offsets xml_i="45983" xml_f="46115" txt_i="29176" txt_f="29308">Primary efficacy outcome (number of oocytes retrieved) for patients randomized to receive either r-hFSH/r-hLH or r-hFSH monotherapy.</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="." span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="." span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"></th><th align="left" colspan="3" rowspan="1"><offsets xml_i="46729" xml_f="46741" txt_i="29309" txt_f="29321">r-hFSH/r-hLH</offsets></th><th align="left" colspan="3" rowspan="1"><offsets xml_i="46787" xml_f="46793" txt_i="29321" txt_f="29327">r-hFSH</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="46839" xml_f="46849" txt_i="29327" txt_f="29337">Unadjusted</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="46895" xml_f="46950" txt_i="29337" txt_f="29392">Adjusted for over-dispersion (Poisson regression model)</offsets></th></tr><tr><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="47013" xml_f="47014" txt_i="29392" txt_f="29393">n</offsets></italic></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47069" xml_f="47078" txt_i="29393" txt_f="29402">Mean (SD)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47124" xml_f="47138" txt_i="29402" txt_f="29416">Median (range)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="47192" xml_f="47193" txt_i="29416" txt_f="29417">n</offsets></italic></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47248" xml_f="47257" txt_i="29417" txt_f="29426">Mean (SD)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47303" xml_f="47317" txt_i="29426" txt_f="29440">Median (range)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47363" xml_f="47396" txt_i="29440" txt_f="29473">Between-group difference (95% CI)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="47450" xml_f="47451" txt_i="29473" txt_f="29474">P</offsets></italic><offsets xml_i="47460" xml_f="47466" txt_i="29474" txt_f="29480">-value</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47512" xml_f="47545" txt_i="29480" txt_f="29513">Between-group difference (95% CI)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="47599" xml_f="47600" txt_i="29513" txt_f="29514">P</offsets></italic><offsets xml_i="47609" xml_f="47615" txt_i="29514" txt_f="29520">-value</offsets></th></tr></thead><tbody><tr><td colspan="11" rowspan="1"><offsets xml_i="47673" xml_f="47676" txt_i="29520" txt_f="29523">ITT</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="47718" xml_f="47726" txt_i="29524" txt_f="29532"> Overall</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47759" xml_f="47762" txt_i="29533" txt_f="29536">462</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47795" xml_f="47805" txt_i="29537" txt_f="29547">3.3 (2.71)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47838" xml_f="47848" txt_i="29548" txt_f="29558">3.0 (0–15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47881" xml_f="47884" txt_i="29559" txt_f="29562">477</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47917" xml_f="47927" txt_i="29563" txt_f="29573">3.6 (2.82)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47960" xml_f="47970" txt_i="29574" txt_f="29584">3.0 (0–16)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48003" xml_f="48022" txt_i="29585" txt_f="29604">–0.24 (−0.47, 0.00)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48055" xml_f="48060" txt_i="29605" txt_f="29610">0.054</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48093" xml_f="48112" txt_i="29611" txt_f="29630">–0.24 (−0.74, 0.27)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48145" xml_f="48150" txt_i="29631" txt_f="29636">0.182</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48192" xml_f="48209" txt_i="29637" txt_f="29651"> Age &lt;35 years</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48242" xml_f="48244" txt_i="29652" txt_f="29654">57</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48277" xml_f="48287" txt_i="29655" txt_f="29665">3.5 (2.96)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48320" xml_f="48330" txt_i="29666" txt_f="29676">3.0 (0–12)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48363" xml_f="48365" txt_i="29677" txt_f="29679">61</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48398" xml_f="48408" txt_i="29680" txt_f="29690">3.3 (2.50)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48441" xml_f="48451" txt_i="29691" txt_f="29701">3.0 (0–13)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="48497" xml_f="48500" txt_i="29702" txt_f="29705">– *</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48533" xml_f="48538" txt_i="29706" txt_f="29711">0.229</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="48584" xml_f="48587" txt_i="29712" txt_f="29715">– *</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48620" xml_f="48625" txt_i="29716" txt_f="29721">0.407</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48667" xml_f="48681" txt_i="29722" txt_f="29736"> Age ≥35 years</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48714" xml_f="48717" txt_i="29737" txt_f="29740">405</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48750" xml_f="48760" txt_i="29741" txt_f="29751">3.3 (2.67)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48793" xml_f="48803" txt_i="29752" txt_f="29762">3.0 (0–15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48836" xml_f="48839" txt_i="29763" txt_f="29766">416</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48872" xml_f="48882" txt_i="29767" txt_f="29777">3.6 (2.86)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48915" xml_f="48925" txt_i="29778" txt_f="29788">3.0 (0–16)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48958" xml_f="48978" txt_i="29789" txt_f="29809">–0.32 (–0.64, –0.01)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49011" xml_f="49016" txt_i="29810" txt_f="29815">0.013</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49049" xml_f="49068" txt_i="29816" txt_f="29835">–0.32 (–0.78, 0.18)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49101" xml_f="49106" txt_i="29836" txt_f="29841">0.085</offsets></td></tr><tr><td colspan="11" rowspan="1"><offsets xml_i="49149" xml_f="49151" txt_i="29842" txt_f="29844">PP</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49193" xml_f="49201" txt_i="29845" txt_f="29853"> Overall</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49234" xml_f="49237" txt_i="29854" txt_f="29857">377</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49270" xml_f="49280" txt_i="29858" txt_f="29868">3.8 (2.67)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49313" xml_f="49323" txt_i="29869" txt_f="29879">3.0 (0–15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49356" xml_f="49359" txt_i="29880" txt_f="29883">395</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49392" xml_f="49402" txt_i="29884" txt_f="29894">4.0 (2.74)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49435" xml_f="49445" txt_i="29895" txt_f="29905">3.0 (0–16)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49478" xml_f="49497" txt_i="29906" txt_f="29925">–0.17 (–0.44, 0.09)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49530" xml_f="49535" txt_i="29926" txt_f="29931">0.202</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49568" xml_f="49587" txt_i="29932" txt_f="29951">–0.17 (–0.72, 0.37)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49620" xml_f="49625" txt_i="29952" txt_f="29957">0.340</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn101"><p><offsets xml_i="49693" xml_f="49839" txt_i="29958" txt_f="30104">*Negative of Hessian not positive definite. ITT, intention-to-treat; PP, per-protocol; r-hFSH, recombinant human FSH; r-hLH, recombinant human LH.</offsets></p></fn></table-wrap-foot></table-wrap></p><p><offsets xml_i="49886" xml_f="50228" txt_i="30106" txt_f="30445">The predefined regression analysis of the primary endpoint included terms for country and age category (&lt;35 versus ≥35 years), in addition to treatment group. Although neither age category nor treatment group had a significant effect on the number of oocytes retrieved, there was a significant interaction between age and treatment group (</offsets><italic><offsets xml_i="50236" xml_f="50239" txt_i="30445" txt_f="30448">P =</offsets></italic><offsets xml_i="50248" xml_f="50366" txt_i="30448" txt_f="30563"> 0.042) indicating that the treatment effect was different between the two age groups. In patients aged &lt;35 years (</offsets><italic><offsets xml_i="50374" xml_f="50375" txt_i="30563" txt_f="30564">n</offsets></italic><offsets xml_i="50384" xml_f="50537" txt_i="30564" txt_f="30717"> = 118) a greater mean number of oocytes retrieved was observed with r-hFSH/r-hLH (3.5) compared with r-hFSH (3.3), whereas, in patients aged ≥35 years (</offsets><italic><offsets xml_i="50545" xml_f="50546" txt_i="30717" txt_f="30718">n</offsets></italic><offsets xml_i="50555" xml_f="50766" txt_i="30718" txt_f="30929"> = 821), a lower mean number of oocytes retrieved was observed with r-hFSH/r-hLH (3.3) compared with r-hFSH (3.6). Furthermore, country was shown to have a significant effect on the number of oocytes retrieved (</offsets><italic><offsets xml_i="50774" xml_f="50775" txt_i="30929" txt_f="30930">P</offsets></italic><offsets xml_i="50784" xml_f="51040" txt_i="30930" txt_f="31183"> &lt; 0.001). However, the interaction between country and treatment group was not significant, indicating that, although the number of oocytes retrieved varied in different countries, the treatment effects were not significantly different among countries.</offsets></p><p><offsets xml_i="51047" xml_f="51113" txt_i="31184" txt_f="31250">Secondary and additional efficacy outcome data are shown in Table </offsets><xref ref-type="table" rid="dew360TB5"><offsets xml_i="51152" xml_f="51154" txt_i="31250" txt_f="31252">IV</offsets></xref><offsets xml_i="51161" xml_f="51463" txt_i="31252" txt_f="31554">. Clinical (14.1% versus 16.8%) and ongoing (11.0% versus 12.4%) pregnancy rates and live birth rate (10.6% versus 11.7%) were similar in both groups (r-hFSH/r-hLH and r-hFSH, respectively), despite the biochemical pregnancy rate being lower with r-hFSH/r-hLH compared with r-hFSH (17.3% versus 23.9%; </offsets><italic><offsets xml_i="51471" xml_f="51472" txt_i="31554" txt_f="31555">P</offsets></italic><offsets xml_i="51481" xml_f="51498" txt_i="31555" txt_f="31572"> = 0.020). Table </offsets><xref ref-type="table" rid="dew360TB6"><offsets xml_i="51537" xml_f="51538" txt_i="31572" txt_f="31573">V</offsets></xref><offsets xml_i="51545" xml_f="51956" txt_i="31573" txt_f="31984"> shows that this corresponds to a lower incidence of total pregnancy outcome failure in patients receiving r-hFSH/r-hLH compared with those receiving r-hFSH alone, in all three relevant study populations investigated (patients receiving at least one dose of study drug [ITT population]; patients receiving an embryo transfer [ET set]; and patients having a positive pregnancy test [biochemical pregnancy set]).
</offsets><table-wrap id="dew360TB5" orientation="portrait" position="float"><label><offsets xml_i="52030" xml_f="52038" txt_i="31984" txt_f="31992">Table IV</offsets></label><caption><p><offsets xml_i="52058" xml_f="52113" txt_i="31992" txt_f="32047">Secondary and other efficacy endpoints (ITT population)</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="." span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="52493" xml_f="52507" txt_i="32048" txt_f="32062">r-hFSH/r-hLH (</offsets><italic><offsets xml_i="52515" xml_f="52516" txt_i="32062" txt_f="32063">n</offsets></italic><offsets xml_i="52525" xml_f="52532" txt_i="32063" txt_f="32070"> = 462)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="52578" xml_f="52586" txt_i="32070" txt_f="32078">r-hFSH (</offsets><italic><offsets xml_i="52594" xml_f="52595" txt_i="32078" txt_f="32079">n</offsets></italic><offsets xml_i="52604" xml_f="52611" txt_i="32079" txt_f="32086"> = 477)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="52657" xml_f="52667" txt_i="32086" txt_f="32096">Odds ratio</offsets><xref ref-type="fn" rid="dew360tfn10"><offsets xml_i="52705" xml_f="52706" txt_i="32096" txt_f="32097">*</offsets></xref><offsets xml_i="52713" xml_f="52749" txt_i="32097" txt_f="32133"> (95% CI) unless otherwise indicated</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="52803" xml_f="52805" txt_i="32133" txt_f="32135">P-</offsets></italic><offsets xml_i="52814" xml_f="52819" txt_i="32135" txt_f="32140">value</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="52876" xml_f="52893" txt_i="32140" txt_f="32157">Cancelled cycles,</offsets><sup><xref ref-type="fn" rid="dew360tfn11"><offsets xml_i="52936" xml_f="52937" txt_i="32157" txt_f="32158">†</offsets></xref></sup><italic><offsets xml_i="52958" xml_f="52959" txt_i="32158" txt_f="32159">n</offsets></italic><offsets xml_i="52968" xml_f="52972" txt_i="32159" txt_f="32163"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53005" xml_f="53013" txt_i="32164" txt_f="32172">35 (7.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53046" xml_f="53054" txt_i="32173" txt_f="32181">32 (6.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53087" xml_f="53104" txt_i="32182" txt_f="32199">1.12 (0.68, 1.85)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53137" xml_f="53142" txt_i="32200" txt_f="32205">0.654</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53184" xml_f="53207" txt_i="32206" txt_f="32229">Biochemical pregnancy, </offsets><italic><offsets xml_i="53215" xml_f="53216" txt_i="32229" txt_f="32230">n</offsets></italic><offsets xml_i="53225" xml_f="53229" txt_i="32230" txt_f="32234"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53262" xml_f="53271" txt_i="32235" txt_f="32244">80 (17.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53304" xml_f="53314" txt_i="32245" txt_f="32255">114 (23.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53347" xml_f="53364" txt_i="32256" txt_f="32273">0.68 (0.49, 0.94)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53397" xml_f="53402" txt_i="32274" txt_f="32279">0.020</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53444" xml_f="53464" txt_i="32280" txt_f="32300">Clinical pregnancy, </offsets><italic><offsets xml_i="53472" xml_f="53473" txt_i="32300" txt_f="32301">n</offsets></italic><offsets xml_i="53482" xml_f="53486" txt_i="32301" txt_f="32305"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53519" xml_f="53528" txt_i="32306" txt_f="32315">65 (14.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53561" xml_f="53570" txt_i="32316" txt_f="32325">80 (16.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53603" xml_f="53620" txt_i="32326" txt_f="32343">0.83 (0.58, 1.20)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53653" xml_f="53658" txt_i="32344" txt_f="32349">0.320</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53700" xml_f="53719" txt_i="32350" txt_f="32369">Ongoing pregnancy, </offsets><italic><offsets xml_i="53727" xml_f="53728" txt_i="32369" txt_f="32370">n</offsets></italic><offsets xml_i="53737" xml_f="53741" txt_i="32370" txt_f="32374"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53774" xml_f="53783" txt_i="32375" txt_f="32384">51 (11.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53816" xml_f="53825" txt_i="32385" txt_f="32394">59 (12.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53858" xml_f="53875" txt_i="32395" txt_f="32412">0.90 (0.60, 1.35)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53908" xml_f="53913" txt_i="32413" txt_f="32418">0.599</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53955" xml_f="53974" txt_i="32419" txt_f="32438">Implantation rate, </offsets><italic><offsets xml_i="53982" xml_f="53983" txt_i="32438" txt_f="32439">n</offsets></italic><offsets xml_i="53992" xml_f="53993" txt_i="32439" txt_f="32440">/</offsets><italic><offsets xml_i="54001" xml_f="54002" txt_i="32440" txt_f="32441">N</offsets></italic><offsets xml_i="54011" xml_f="54015" txt_i="32441" txt_f="32445"> (%)</offsets><sup><xref ref-type="fn" rid="dew360tfn12"><offsets xml_i="54058" xml_f="54059" txt_i="32445" txt_f="32446">‡</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="54105" xml_f="54118" txt_i="32447" txt_f="32460">79/538 (14.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54151" xml_f="54164" txt_i="32461" txt_f="32474">93/597 (15.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54197" xml_f="54214" txt_i="32475" txt_f="32492">0.93 (0.67, 1.29)</offsets><sup><xref ref-type="fn" rid="dew360tfn13"><offsets xml_i="54257" xml_f="54258" txt_i="32492" txt_f="32493">§</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="54304" xml_f="54309" txt_i="32494" txt_f="32499">0.675</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="54351" xml_f="54363" txt_i="32500" txt_f="32512">Live birth, </offsets><italic><offsets xml_i="54371" xml_f="54372" txt_i="32512" txt_f="32513">n</offsets></italic><offsets xml_i="54381" xml_f="54385" txt_i="32513" txt_f="32517"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54418" xml_f="54427" txt_i="32518" txt_f="32527">49 (10.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54460" xml_f="54469" txt_i="32528" txt_f="32537">56 (11.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54502" xml_f="54519" txt_i="32538" txt_f="32555">0.91 (0.60, 1.38)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54552" xml_f="54557" txt_i="32556" txt_f="32561">0.663</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="54599" xml_f="54642" txt_i="32562" txt_f="32605">Total FSH dose administered (IU), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54675" xml_f="54691" txt_i="32606" txt_f="32622">3997.7 (1188.33)</offsets><sup><xref ref-type="fn" rid="dew360tfn15"><offsets xml_i="54734" xml_f="54735" txt_i="32622" txt_f="32623">‖</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="54781" xml_f="54797" txt_i="32624" txt_f="32640">4113.6 (1193.93)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54830" xml_f="54851" txt_i="32641" txt_f="32662">–119.3 (–269.9, 31.3)</offsets><sup><xref ref-type="fn" rid="dew360tfn13"><offsets xml_i="54894" xml_f="54895" txt_i="32662" txt_f="32663">§</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="54941" xml_f="54946" txt_i="32664" txt_f="32669">0.120</offsets></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="54988" xml_f="55037" txt_i="32670" txt_f="32719">Number of MII oocytes in ICSI patients, mean (SD)</offsets></td><td rowspan="2" colspan="1"><offsets xml_i="55070" xml_f="55080" txt_i="32720" txt_f="32730">2.9 (2.07)</offsets><sup><xref ref-type="fn" rid="dew360tfn15"><offsets xml_i="55123" xml_f="55124" txt_i="32730" txt_f="32731">¶</offsets></xref></sup></td><td rowspan="2" colspan="1"><offsets xml_i="55170" xml_f="55180" txt_i="32732" txt_f="32742">3.1 (2.14)</offsets><xref ref-type="fn" rid="dew360tfn14"><offsets xml_i="55218" xml_f="55220" txt_i="32742" txt_f="32744">**</offsets></xref></td><td align="left" rowspan="1" colspan="1"><italic><offsets xml_i="55281" xml_f="55292" txt_i="32745" txt_f="32756">Unadjusted:</offsets></italic><offsets xml_i="55301" xml_f="55321" txt_i="32756" txt_f="32776"> –0.24 (–0.64, 0.15)</offsets></td><td align="left" rowspan="1" colspan="1"><italic><offsets xml_i="55375" xml_f="55386" txt_i="32777" txt_f="32788">Unadjusted:</offsets></italic><offsets xml_i="55395" xml_f="55401" txt_i="32788" txt_f="32794"> 0.063</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic><offsets xml_i="55464" xml_f="55493" txt_i="32795" txt_f="32824">Adjusted for over-dispersion:</offsets></italic><offsets xml_i="55502" xml_f="55522" txt_i="32824" txt_f="32844"> –0.24 (–0.72, 0.23)</offsets></td><td align="left" rowspan="1" colspan="1"><italic><offsets xml_i="55576" xml_f="55605" txt_i="32845" txt_f="32874">Adjusted for over-dispersion:</offsets></italic><offsets xml_i="55614" xml_f="55620" txt_i="32874" txt_f="32880"> 0.124</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn10"><p><sup><offsets xml_i="55692" xml_f="55693" txt_i="32881" txt_f="32882">*</offsets></sup><offsets xml_i="55699" xml_f="55726" txt_i="32882" txt_f="32909">r-hFSH/r-hLH versus r-hFSH.</offsets></p></fn><fn id="dew360tfn11"><p><sup><offsets xml_i="55764" xml_f="55765" txt_i="32910" txt_f="32911">†</offsets></sup><offsets xml_i="55771" xml_f="55832" txt_i="32911" txt_f="32972">All cycle cancellations were due to lack of ovarian response.</offsets></p></fn><fn id="dew360tfn12"><p><sup><offsets xml_i="55870" xml_f="55871" txt_i="32973" txt_f="32974">‡</offsets></sup><italic><offsets xml_i="55885" xml_f="55886" txt_i="32974" txt_f="32975">n</offsets></italic><offsets xml_i="55895" xml_f="55967" txt_i="32975" txt_f="33047"> is the number of foetal sacs identified by transvaginal ultrasound and </offsets><italic><offsets xml_i="55975" xml_f="55976" txt_i="33047" txt_f="33048">N</offsets></italic><offsets xml_i="55985" xml_f="56029" txt_i="33048" txt_f="33092"> is the total number of embryos transferred.</offsets></p></fn><fn id="dew360tfn13"><p><sup><offsets xml_i="56067" xml_f="56068" txt_i="33093" txt_f="33094">§</offsets></sup><offsets xml_i="56074" xml_f="56123" txt_i="33094" txt_f="33143">Data are mean difference between groups (95% CI).</offsets></p></fn><fn id="dew360tfn14"><p><sup><offsets xml_i="56161" xml_f="56163" txt_i="33144" txt_f="33146">**</offsets></sup><offsets xml_i="56169" xml_f="56267" txt_i="33146" txt_f="33244">381 patients receiving r-hFSH underwent ICSI and data were not available for 15 of these patients.</offsets></p></fn><fn id="dew360tfn15"><p><sup><offsets xml_i="56305" xml_f="56307" txt_i="33245" txt_f="33247">||</offsets></sup><offsets xml_i="56313" xml_f="56343" txt_i="33247" txt_f="33277">Data missing for 10 patients. </offsets><sup><offsets xml_i="56348" xml_f="56349" txt_i="33277" txt_f="33278">¶</offsets></sup><offsets xml_i="56355" xml_f="56568" txt_i="33278" txt_f="33491">360 patients receiving r-hFSH plus r-hLH underwent ICSI, and data are not available for 13 of these patients. ITT, intention-to-treat; MII, metaphase II; r-hFSH, recombinant human FSH; r-hLH, recombinant human LH.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="dew360TB6" orientation="portrait" position="float"><label><offsets xml_i="56682" xml_f="56689" txt_i="33492" txt_f="33499">Table V</offsets></label><caption><p><offsets xml_i="56709" xml_f="56740" txt_i="33499" txt_f="33530">Total pregnancy outcome failure</offsets><xref ref-type="fn" rid="dew360tfn16"><offsets xml_i="56778" xml_f="56779" txt_i="33530" txt_f="33531">*</offsets></xref><offsets xml_i="56786" xml_f="56787" txt_i="33531" txt_f="33532">.</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="." span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="57167" xml_f="57179" txt_i="33533" txt_f="33545">r-hFSH/r-hLH</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="57225" xml_f="57231" txt_i="33545" txt_f="33551">r-hFSH</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="57277" xml_f="57287" txt_i="33551" txt_f="33561">Odds ratio</offsets><sup><xref ref-type="fn" rid="dew360tfn17"><offsets xml_i="57330" xml_f="57331" txt_i="33561" txt_f="33562">†</offsets></xref></sup><offsets xml_i="57344" xml_f="57353" txt_i="33562" txt_f="33571"> (95% CI)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="57407" xml_f="57409" txt_i="33571" txt_f="33573">P-</offsets></italic><offsets xml_i="57418" xml_f="57423" txt_i="33573" txt_f="33578">value</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="57480" xml_f="57530" txt_i="33578" txt_f="33628">Total pregnancy outcome failure (ITT population), </offsets><italic><offsets xml_i="57538" xml_f="57539" txt_i="33628" txt_f="33629">n</offsets></italic><offsets xml_i="57548" xml_f="57549" txt_i="33629" txt_f="33630">/</offsets><italic><offsets xml_i="57557" xml_f="57558" txt_i="33630" txt_f="33631">N</offsets></italic><offsets xml_i="57567" xml_f="57571" txt_i="33631" txt_f="33635"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57604" xml_f="57616" txt_i="33636" txt_f="33648">31/462 (6.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57649" xml_f="57662" txt_i="33649" txt_f="33662">59/477 (12.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57695" xml_f="57712" txt_i="33663" txt_f="33680">0.52 (0.33, 0.82)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57745" xml_f="57750" txt_i="33681" txt_f="33686">0.005</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="57792" xml_f="57834" txt_i="33687" txt_f="33729">Total pregnancy outcome failure (ET set), </offsets><italic><offsets xml_i="57842" xml_f="57843" txt_i="33729" txt_f="33730">n</offsets></italic><offsets xml_i="57852" xml_f="57853" txt_i="33730" txt_f="33731">/</offsets><italic><offsets xml_i="57861" xml_f="57862" txt_i="33731" txt_f="33732">N</offsets></italic><offsets xml_i="57871" xml_f="57875" txt_i="33732" txt_f="33736"> (%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="57921" xml_f="57933" txt_i="33737" txt_f="33749">31/319 (9.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="57979" xml_f="57992" txt_i="33750" txt_f="33763">59/349 (16.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="58038" xml_f="58055" txt_i="33764" txt_f="33781">0.53 (0.33, 0.84)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="58101" xml_f="58106" txt_i="33782" txt_f="33787">0.007</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="58148" xml_f="58220" txt_i="33788" txt_f="33860">Total pregnancy outcome failure in subjects with biochemical pregnancy, </offsets><italic><offsets xml_i="58228" xml_f="58229" txt_i="33860" txt_f="33861">n</offsets></italic><offsets xml_i="58238" xml_f="58239" txt_i="33861" txt_f="33862">/</offsets><italic><offsets xml_i="58247" xml_f="58248" txt_i="33862" txt_f="33863">N</offsets></italic><offsets xml_i="58257" xml_f="58261" txt_i="33863" txt_f="33867"> (%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="58307" xml_f="58319" txt_i="33868" txt_f="33880">31/80 (38.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="58365" xml_f="58378" txt_i="33881" txt_f="33894">59/114 (51.8)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="58424" xml_f="58441" txt_i="33895" txt_f="33912">0.54 (0.29, 1.01)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="58487" xml_f="58492" txt_i="33913" txt_f="33918">0.052</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn16"><p><sup><offsets xml_i="58564" xml_f="58565" txt_i="33919" txt_f="33920">*</offsets></sup><offsets xml_i="58571" xml_f="58720" txt_i="33920" txt_f="34069">Total pregnancy outcome failure was defined as the combination of preclinical miscarriage, clinical miscarriage (early + late) and ectopic pregnancy.</offsets></p></fn><fn id="dew360tfn17"><p><sup><offsets xml_i="58758" xml_f="58759" txt_i="34070" txt_f="34071">†</offsets></sup><offsets xml_i="58765" xml_f="58792" txt_i="34071" txt_f="34098">r-hFSH/r-hLH versus r-hFSH.</offsets></p></fn><fn id="dew360tfn18"><p><offsets xml_i="58825" xml_f="58947" txt_i="34099" txt_f="34221">ET set, embryo transfer analysis set; ITT, intention-to-treat; r-hFSH, recombinant human FSH; r-hLH, recombinant human LH.</offsets></p></fn></table-wrap-foot></table-wrap></p><p><offsets xml_i="58994" xml_f="58999" txt_i="34223" txt_f="34228">In a </offsets><italic><offsets xml_i="59007" xml_f="59015" txt_i="34228" txt_f="34236">post hoc</offsets></italic><offsets xml_i="59024" xml_f="59126" txt_i="34236" txt_f="34338"> analysis, the impact of BSC on the live birth rate according to treatment group was explored (Tables </offsets><xref ref-type="table" rid="dew360TB7"><offsets xml_i="59165" xml_f="59167" txt_i="34338" txt_f="34340">VI</offsets></xref><offsets xml_i="59174" xml_f="59179" txt_i="34340" txt_f="34345"> and </offsets><xref ref-type="table" rid="dew360TB8"><offsets xml_i="59218" xml_f="59221" txt_i="34345" txt_f="34348">VII</offsets></xref><offsets xml_i="59228" xml_f="59384" txt_i="34348" txt_f="34504">). The live birth rate calculated for each BSC category and each treatment group suggested a difference of the treatment effect depending on the BSC (Table </offsets><xref ref-type="table" rid="dew360TB7"><offsets xml_i="59423" xml_f="59425" txt_i="34504" txt_f="34506">VI</offsets></xref><offsets xml_i="59432" xml_f="59478" txt_i="34506" txt_f="34552">). In the logistic regression analysis (Table </offsets><xref ref-type="table" rid="dew360TB8"><offsets xml_i="59517" xml_f="59520" txt_i="34552" txt_f="34555">VII</offsets></xref><offsets xml_i="59527" xml_f="59630" txt_i="34555" txt_f="34658">), in the ITT population, the parameter estimate (SE) of treatment (referent: r-hFSH) was –0.79 (0.30; </offsets><italic><offsets xml_i="59638" xml_f="59639" txt_i="34658" txt_f="34659">P</offsets></italic><offsets xml_i="59648" xml_f="59686" txt_i="34659" txt_f="34697"> = 0.008) and of BSC was –1.09 (0.25; </offsets><italic><offsets xml_i="59694" xml_f="59695" txt_i="34697" txt_f="34698">P</offsets></italic><offsets xml_i="59704" xml_f="59800" txt_i="34698" txt_f="34791"> &lt; 0.001); the interaction of treatment and BSC had a parameter estimate (SE) of 1.05 (0.33; </offsets><italic><offsets xml_i="59808" xml_f="59809" txt_i="34791" txt_f="34792">P</offsets></italic><offsets xml_i="59818" xml_f="60112" txt_i="34792" txt_f="35086"> = 0.001). The live birth rate in the r-hFSH group appeared to be lower in women with moderate POR (BSC = 1) and women with severe POR (BSC = 2) compared with those with mild POR (BSC = 0), whereas in the r-hFSH/r-hLH group the live birth rate was similar across all POR severity levels (Table </offsets><xref ref-type="table" rid="dew360TB7"><offsets xml_i="60151" xml_f="60153" txt_i="35086" txt_f="35088">VI</offsets></xref><offsets xml_i="60160" xml_f="60163" txt_i="35088" txt_f="35091">).
</offsets><table-wrap id="dew360TB7" orientation="portrait" position="float"><label><offsets xml_i="60237" xml_f="60245" txt_i="35091" txt_f="35099">Table VI</offsets></label><caption><p><offsets xml_i="60265" xml_f="60341" txt_i="35099" txt_f="35175">Observed (unadjusted) live birth rates according to BSC and treatment group.</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"><offsets xml_i="60741" xml_f="60744" txt_i="35176" txt_f="35179">BSC</offsets></th><th align="left" rowspan="2" colspan="1"><offsets xml_i="60790" xml_f="60824" txt_i="35179" txt_f="35213">Patients with a previous ART cycle</offsets></th><th align="left" rowspan="2" colspan="1"><offsets xml_i="60870" xml_f="60905" txt_i="35213" txt_f="35248">Patients with no previous ART cycle</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="60951" xml_f="60965" txt_i="35248" txt_f="35262">r-hFSH/r-hLH (</offsets><italic><offsets xml_i="60973" xml_f="60974" txt_i="35262" txt_f="35263">N</offsets></italic><offsets xml_i="60983" xml_f="60990" txt_i="35263" txt_f="35270"> = 462)</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="61036" xml_f="61044" txt_i="35270" txt_f="35278">r-hFSH (</offsets><italic><offsets xml_i="61052" xml_f="61053" txt_i="35278" txt_f="35279">N</offsets></italic><offsets xml_i="61062" xml_f="61069" txt_i="35279" txt_f="35286"> = 477)</offsets></th></tr><tr><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="61132" xml_f="61133" txt_i="35286" txt_f="35287">n</offsets></italic><offsets xml_i="61142" xml_f="61145" txt_i="35287" txt_f="35290"> (%</offsets><xref ref-type="fn" rid="dew360tfn19"><offsets xml_i="61183" xml_f="61184" txt_i="35290" txt_f="35291">*</offsets></xref><offsets xml_i="61191" xml_f="61192" txt_i="35291" txt_f="35292">)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="61238" xml_f="61255" txt_i="35292" txt_f="35309">Live birth rate, </offsets><italic><offsets xml_i="61263" xml_f="61264" txt_i="35309" txt_f="35310">n</offsets></italic><offsets xml_i="61273" xml_f="61276" txt_i="35310" txt_f="35313"> (%</offsets><sup><xref ref-type="fn" rid="dew360tfn20"><offsets xml_i="61319" xml_f="61320" txt_i="35313" txt_f="35314">†</offsets></xref></sup><offsets xml_i="61333" xml_f="61334" txt_i="35314" txt_f="35315">)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="61388" xml_f="61389" txt_i="35315" txt_f="35316">n</offsets></italic><offsets xml_i="61398" xml_f="61401" txt_i="35316" txt_f="35319"> (%</offsets><xref ref-type="fn" rid="dew360tfn19"><offsets xml_i="61439" xml_f="61440" txt_i="35319" txt_f="35320">*</offsets></xref><offsets xml_i="61447" xml_f="61448" txt_i="35320" txt_f="35321">)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="61494" xml_f="61511" txt_i="35321" txt_f="35338">Live birth rate, </offsets><italic><offsets xml_i="61519" xml_f="61520" txt_i="35338" txt_f="35339">n</offsets></italic><offsets xml_i="61529" xml_f="61532" txt_i="35339" txt_f="35342"> (%</offsets><sup><xref ref-type="fn" rid="dew360tfn20"><offsets xml_i="61575" xml_f="61576" txt_i="35342" txt_f="35343">†</offsets></xref></sup><offsets xml_i="61589" xml_f="61590" txt_i="35343" txt_f="35344">)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="61647" xml_f="61655" txt_i="35344" txt_f="35352">0 (mild)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="61688" xml_f="61705" txt_i="35353" txt_f="35367">&lt;40 years old </offsets><bold><offsets xml_i="61711" xml_f="61714" txt_i="35367" txt_f="35370">AND</offsets></bold><offsets xml_i="61721" xml_f="61766" txt_i="35370" txt_f="35415"> previous ART cycle with ≥2 oocytes retrieved</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="61799" xml_f="61816" txt_i="35416" txt_f="35430">&lt;40 years old </offsets><bold><offsets xml_i="61822" xml_f="61825" txt_i="35430" txt_f="35433">AND</offsets></bold><offsets xml_i="61832" xml_f="61851" txt_i="35433" txt_f="35449"> AMH &gt; 0.5 ng/ml</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="61884" xml_f="61894" txt_i="35450" txt_f="35460">170 (36.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="61927" xml_f="61936" txt_i="35461" txt_f="35470">18 (10.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="61969" xml_f="61979" txt_i="35471" txt_f="35481">156 (32.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62012" xml_f="62021" txt_i="35482" txt_f="35491">34 (21.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="62063" xml_f="62075" txt_i="35492" txt_f="35504">1 (moderate)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62108" xml_f="62122" txt_i="35505" txt_f="35519">≥40 years old </offsets><bold><offsets xml_i="62128" xml_f="62130" txt_i="35519" txt_f="35521">OR</offsets></bold><offsets xml_i="62137" xml_f="62185" txt_i="35521" txt_f="35566"> previous ART cycle with &lt;2 oocytes retrieved</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62218" xml_f="62232" txt_i="35567" txt_f="35581">≥40 years old </offsets><bold><offsets xml_i="62238" xml_f="62240" txt_i="35581" txt_f="35583">OR</offsets></bold><offsets xml_i="62247" xml_f="62263" txt_i="35583" txt_f="35599"> AMH ≤ 0.5 ng/ml</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62296" xml_f="62306" txt_i="35600" txt_f="35610">209 (45.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62339" xml_f="62348" txt_i="35611" txt_f="35620">23 (11.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62381" xml_f="62391" txt_i="35621" txt_f="35631">254 (53.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62424" xml_f="62432" txt_i="35632" txt_f="35640">19 (7.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="62474" xml_f="62484" txt_i="35641" txt_f="35651">2 (severe)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62517" xml_f="62531" txt_i="35652" txt_f="35666">≥40 years old </offsets><bold><offsets xml_i="62537" xml_f="62540" txt_i="35666" txt_f="35669">AND</offsets></bold><offsets xml_i="62547" xml_f="62595" txt_i="35669" txt_f="35714"> previous ART cycle with &lt;2 oocytes retrieved</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62628" xml_f="62642" txt_i="35715" txt_f="35729">≥40 years old </offsets><bold><offsets xml_i="62648" xml_f="62651" txt_i="35729" txt_f="35732">AND</offsets></bold><offsets xml_i="62658" xml_f="62674" txt_i="35732" txt_f="35748"> AMH ≤ 0.5 ng/ml</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62707" xml_f="62716" txt_i="35749" txt_f="35758">83 (18.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62749" xml_f="62756" txt_i="35759" txt_f="35766">8 (9.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62789" xml_f="62798" txt_i="35767" txt_f="35776">67 (14.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62831" xml_f="62838" txt_i="35777" txt_f="35784">3 (4.5)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="62880" xml_f="62887" txt_i="35785" txt_f="35792">Overall</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62920" xml_f="62931" txt_i="35793" txt_f="35804">462 (100.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="62964" xml_f="62973" txt_i="35805" txt_f="35814">49 (10.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="63006" xml_f="63017" txt_i="35815" txt_f="35826">477 (100.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="63050" xml_f="63059" txt_i="35827" txt_f="35836">56 (11.7)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn19"><p><sup><offsets xml_i="63131" xml_f="63132" txt_i="35837" txt_f="35838">*</offsets></sup><offsets xml_i="63138" xml_f="63194" txt_i="35838" txt_f="35894">Percentage of total population receiving each treatment.</offsets></p></fn><fn id="dew360tfn20"><p><sup><offsets xml_i="63232" xml_f="63233" txt_i="35895" txt_f="35896">†</offsets></sup><offsets xml_i="63239" xml_f="63298" txt_i="35896" txt_f="35955">Percentage of population with BSC score for each treatment.</offsets></p></fn><fn id="dew360tfn21"><p><offsets xml_i="63331" xml_f="63420" txt_i="35956" txt_f="36045">BSC, baseline severity score; r-hFSH, recombinant human FSH; r-hLH, recombinant human LH.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="dew360TB8" orientation="portrait" position="float"><label><offsets xml_i="63534" xml_f="63543" txt_i="36046" txt_f="36055">Table VII</offsets></label><caption><p><offsets xml_i="63563" xml_f="63634" txt_i="36055" txt_f="36126">Live birth rate—logistic regression model with treatment group and BSC.</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="." span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="." span="1"></col></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"><offsets xml_i="63968" xml_f="63975" txt_i="36127" txt_f="36134">Effects</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="64021" xml_f="64035" txt_i="36134" txt_f="36148">ITT population</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="64081" xml_f="64094" txt_i="36148" txt_f="36161">PP population</offsets></th></tr><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="64149" xml_f="64172" txt_i="36161" txt_f="36184">Parameter estimate (SE)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="64226" xml_f="64228" txt_i="36184" txt_f="36186">P-</offsets></italic><offsets xml_i="64237" xml_f="64242" txt_i="36186" txt_f="36191">value</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="64288" xml_f="64311" txt_i="36191" txt_f="36214">Parameter estimate (SE)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="64365" xml_f="64367" txt_i="36214" txt_f="36216">P-</offsets></italic><offsets xml_i="64376" xml_f="64381" txt_i="36216" txt_f="36221">value</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="64438" xml_f="64447" txt_i="36221" txt_f="36230">Intercept</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64480" xml_f="64492" txt_i="36231" txt_f="36243">–1.32 (0.19)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64525" xml_f="64534" txt_i="36244" txt_f="36250">&lt;0.001</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64567" xml_f="64579" txt_i="36251" txt_f="36263">–1.45 (0.22)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64612" xml_f="64621" txt_i="36264" txt_f="36270">&lt;0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="64663" xml_f="64672" txt_i="36271" txt_f="36280">Treatment</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64705" xml_f="64717" txt_i="36281" txt_f="36293">–0.79 (0.30)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64750" xml_f="64755" txt_i="36294" txt_f="36299">0.008</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64788" xml_f="64800" txt_i="36300" txt_f="36312">–0.60 (0.33)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64833" xml_f="64838" txt_i="36313" txt_f="36318">0.068</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="64880" xml_f="64883" txt_i="36319" txt_f="36322">BSC</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64916" xml_f="64928" txt_i="36323" txt_f="36335">–1.09 (0.25)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="64961" xml_f="64970" txt_i="36336" txt_f="36342">&lt;0.001</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="65003" xml_f="65015" txt_i="36343" txt_f="36355">–0.84 (0.27)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="65048" xml_f="65053" txt_i="36356" txt_f="36361">0.002</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="65095" xml_f="65110" txt_i="36362" txt_f="36377">Treatment · BSC</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="65143" xml_f="65154" txt_i="36378" txt_f="36389">1.05 (0.33)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="65187" xml_f="65192" txt_i="36390" txt_f="36395">0.001</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="65225" xml_f="65236" txt_i="36396" txt_f="36407">0.90 (0.35)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="65269" xml_f="65274" txt_i="36408" txt_f="36413">0.009</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn22"><p><offsets xml_i="65341" xml_f="65443" txt_i="36414" txt_f="36516">Reference BSC: BSC = 0 (mild); reference treatment: r-hFSH; ITT, intention-to-treat; PP, per-protocol.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec id="dew360s15b"><title><offsets xml_i="65521" xml_f="65538" txt_i="36519" txt_f="36536">Safety evaluation</offsets></title><p><offsets xml_i="65549" xml_f="65629" txt_i="36537" txt_f="36617">One patient who received r-hFSH/r-hLH experienced one event of mild early OHSS (</offsets><xref ref-type="supplementary-material" rid="sup2"><offsets xml_i="65680" xml_f="65698" txt_i="36617" txt_f="36635">Supplementary Data</offsets></xref><offsets xml_i="65705" xml_f="65747" txt_i="36635" txt_f="36677">), and no other OHSS events were reported.</offsets></p><p><offsets xml_i="65754" xml_f="65937" txt_i="36678" txt_f="36861">The overall incidence of TEAEs was generally similar between the two treatment groups, occurring in 25.8% and 33.3% of women treated with r-hFSH/r-hLH and r-hFSH, respectively (Table </offsets><xref ref-type="table" rid="dew360TB9"><offsets xml_i="65976" xml_f="65980" txt_i="36861" txt_f="36865">VIII</offsets></xref><offsets xml_i="65987" xml_f="66747" txt_i="36865" txt_f="37625">). The majority of the TEAEs occurred during the stimulation and post-stimulation phases, with a low number of these assessed by the investigator as being related to either r-hFSH/r-hLH or r-hFSH (occurring in 4.8% and 4.2% of women, respectively). Most TEAEs were mild or moderate in severity in both treatment groups. Two women (0.4%) discontinued treatment with r-hFSH/r-hLH because of TEAEs compared with four (0.8%) patients who discontinued r-hFSH. The TEAEs leading to discontinuation of r-hFSH/r-hLH were ovarian rupture (post-oocyte retrieval ovarian bleeding requiring laparoscopy) and endometrial polyps. The TEAEs leading to discontinuation of r-hFSH were overdose (asymptomatic), herniated cervical vertebral disc, ovarian cyst and ovarian polyp.
</offsets><table-wrap id="dew360TB9" orientation="portrait" position="float"><label><offsets xml_i="66821" xml_f="66831" txt_i="37625" txt_f="37635">Table VIII</offsets></label><caption><p><offsets xml_i="66851" xml_f="66898" txt_i="37635" txt_f="37682">Overview of adverse events (safety population).</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char=" " span="1"></col><col align="char" char=" " span="1"></col><col align="char" char="(" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="67236" xml_f="67251" txt_i="37683" txt_f="37698">r-hFSH/ r-hLH (</offsets><italic><offsets xml_i="67259" xml_f="67260" txt_i="37698" txt_f="37699">n</offsets></italic><offsets xml_i="67269" xml_f="67276" txt_i="37699" txt_f="37706"> = 462)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="67322" xml_f="67330" txt_i="37706" txt_f="37714">r-hFSH (</offsets><italic><offsets xml_i="67338" xml_f="67339" txt_i="37714" txt_f="37715">n</offsets></italic><offsets xml_i="67348" xml_f="67355" txt_i="37715" txt_f="37722"> = 477)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="67401" xml_f="67420" txt_i="37722" txt_f="37741">Odds ratio (95% CI)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="67477" xml_f="67504" txt_i="37741" txt_f="37768">AE prior to down-regulation</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67537" xml_f="67545" txt_i="37769" txt_f="37777">38 (8.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67578" xml_f="67586" txt_i="37778" txt_f="37786">36 (7.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67619" xml_f="67636" txt_i="37787" txt_f="37804">1.12 (0.69, 1.82)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="67678" xml_f="67682" txt_i="37805" txt_f="37809">TEAE</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67715" xml_f="67725" txt_i="37810" txt_f="37820">119 (25.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67758" xml_f="67768" txt_i="37821" txt_f="37831">159 (33.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67801" xml_f="67818" txt_i="37832" txt_f="37849">0.67 (0.49, 0.91)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="67860" xml_f="67893" txt_i="37850" txt_f="37883">TEAE during down-regulation phase</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67926" xml_f="67935" txt_i="37884" txt_f="37893">59 (12.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="67968" xml_f="67977" txt_i="37894" txt_f="37903">75 (15.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68010" xml_f="68027" txt_i="37904" txt_f="37921">0.76 (0.51, 1.14)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="68069" xml_f="68119" txt_i="37922" txt_f="37972">TEAE during stimulation and post-stimulation phase</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68152" xml_f="68161" txt_i="37973" txt_f="37982">92 (19.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68194" xml_f="68204" txt_i="37983" txt_f="37993">128 (26.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68237" xml_f="68254" txt_i="37994" txt_f="38011">0.67 (0.48, 0.92)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="68296" xml_f="68368" txt_i="38012" txt_f="38084">TEAE related to study drug during stimulation and post-stimulation phase</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68401" xml_f="68409" txt_i="38085" txt_f="38093">23 (5.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68442" xml_f="68450" txt_i="38094" txt_f="38102">20 (4.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68483" xml_f="68500" txt_i="38103" txt_f="38120">1.28 (0.68, 2.44)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="68542" xml_f="68554" txt_i="38121" txt_f="38133">Serious TEAE</offsets><sup><xref ref-type="fn" rid="dew360tfn23"><offsets xml_i="68597" xml_f="68598" txt_i="38133" txt_f="38134">*</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="68644" xml_f="68651" txt_i="38135" txt_f="38142">8 (1.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68684" xml_f="68692" txt_i="38143" txt_f="38151">17 (3.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68725" xml_f="68742" txt_i="38152" txt_f="38169">0.46 (0.19, 1.09)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="68784" xml_f="68826" txt_i="38170" txt_f="38212">TEAE resulting in withdrawal of study drug</offsets><sup><xref ref-type="fn" rid="dew360tfn24"><offsets xml_i="68869" xml_f="68870" txt_i="38212" txt_f="38213">†</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="68916" xml_f="68917" txt_i="38214" txt_f="38215">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="68950" xml_f="68957" txt_i="38216" txt_f="38223">2 (0.4)</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="69032" xml_f="69069" txt_i="38225" txt_f="38262">TEAE leading to trial discontinuation</offsets><sup><xref ref-type="fn" rid="dew360tfn24"><offsets xml_i="69112" xml_f="69113" txt_i="38262" txt_f="38263">†</offsets></xref></sup></td><td rowspan="1" colspan="1"><offsets xml_i="69159" xml_f="69166" txt_i="38264" txt_f="38271">2 (0.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="69199" xml_f="69206" txt_i="38272" txt_f="38279">4 (0.8)</offsets></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn23"><p><sup><offsets xml_i="69311" xml_f="69312" txt_i="38281" txt_f="38282">*</offsets></sup><offsets xml_i="69318" xml_f="69396" txt_i="38282" txt_f="38360">All serious TEAEs occurred during the stimulation and post-stimulation phases.</offsets></p></fn><fn id="dew360tfn24"><p><sup><offsets xml_i="69434" xml_f="69435" txt_i="38361" txt_f="38362">†</offsets></sup><offsets xml_i="69441" xml_f="69496" txt_i="38362" txt_f="38417">Subject counts too small for meaningful OR calculation.</offsets></p></fn><fn id="dew360tfn25"><p><offsets xml_i="69529" xml_f="69555" txt_i="38418" txt_f="38444">All data are presented as </offsets><italic><offsets xml_i="69563" xml_f="69564" txt_i="38444" txt_f="38445">n</offsets></italic><offsets xml_i="69573" xml_f="69697" txt_i="38445" txt_f="38569"> (%). AE, adverse event; TEAE, treatment-emergent adverse event; r-hFSH, recombinant human FSH; r-hLH, recombinant human LH.</offsets></p></fn></table-wrap-foot></table-wrap></p><p><offsets xml_i="69744" xml_f="69915" txt_i="38571" txt_f="38742">An observed lower proportion of patients receiving r-hFSH/r-hLH compared with those receiving r-hFSH experienced TEAEs during the stimulation and post-stimulation phases (</offsets><italic><offsets xml_i="69923" xml_f="69924" txt_i="38742" txt_f="38743">n</offsets></italic><offsets xml_i="69933" xml_f="69954" txt_i="38743" txt_f="38764"> = 92 [19.9%] versus </offsets><italic><offsets xml_i="69962" xml_f="69963" txt_i="38764" txt_f="38765">n</offsets></italic><offsets xml_i="69972" xml_f="70065" txt_i="38765" txt_f="38858"> = 128 [26.8%]). A large proportion of these TEAEs were mild or moderate in intensity (Table </offsets><xref ref-type="table" rid="dew360TB10"><offsets xml_i="70105" xml_f="70107" txt_i="38858" txt_f="38860">IX</offsets></xref><offsets xml_i="70114" xml_f="70117" txt_i="38860" txt_f="38863">).
</offsets><table-wrap id="dew360TB10" orientation="portrait" position="float"><label><offsets xml_i="70192" xml_f="70200" txt_i="38863" txt_f="38871">Table IX</offsets></label><caption><p><offsets xml_i="70220" xml_f="70349" txt_i="38871" txt_f="39000">Overview of the proportion of patients experiencing TEAEs during the stimulation and post-stimulation phases (safety population).</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char=" " span="1"></col><col align="char" char=" " span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="70645" xml_f="70659" txt_i="39001" txt_f="39015">r-hFSH/r-hLH (</offsets><italic><offsets xml_i="70667" xml_f="70668" txt_i="39015" txt_f="39016">n</offsets></italic><offsets xml_i="70677" xml_f="70684" txt_i="39016" txt_f="39023"> = 462)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="70730" xml_f="70738" txt_i="39023" txt_f="39031">r-hFSH (</offsets><italic><offsets xml_i="70746" xml_f="70747" txt_i="39031" txt_f="39032">n</offsets></italic><offsets xml_i="70756" xml_f="70763" txt_i="39032" txt_f="39039"> = 477)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="70820" xml_f="70844" txt_i="39039" txt_f="39063">Nervous system disorders</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="70877" xml_f="70885" txt_i="39064" txt_f="39072">36 (7.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="70918" xml_f="70926" txt_i="39073" txt_f="39081">38 (8.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="70968" xml_f="70994" txt_i="39082" txt_f="39108">Gastrointestinal disorders</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71027" xml_f="71035" txt_i="39109" txt_f="39117">29 (6.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71068" xml_f="71076" txt_i="39118" txt_f="39126">35 (7.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="71118" xml_f="71164" txt_i="39127" txt_f="39173">Pregnancy, puerperium and perinatal conditions</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71197" xml_f="71205" txt_i="39174" txt_f="39182">17 (3.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71238" xml_f="71246" txt_i="39183" txt_f="39191">32 (6.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="71288" xml_f="71328" txt_i="39192" txt_f="39232">Reproductive system and breast disorders</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71361" xml_f="71369" txt_i="39233" txt_f="39241">13 (2.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71402" xml_f="71410" txt_i="39242" txt_f="39250">20 (4.2)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="71452" xml_f="71488" txt_i="39251" txt_f="39287">Maximum severity of TEAE experienced</offsets><sup><xref ref-type="fn" rid="dew360tfn26"><offsets xml_i="71531" xml_f="71532" txt_i="39287" txt_f="39288">*</offsets></xref></sup></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="71587" xml_f="71595" txt_i="39289" txt_f="39297"> No TEAE</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71628" xml_f="71638" txt_i="39298" txt_f="39308">370 (80.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71671" xml_f="71681" txt_i="39309" txt_f="39319">349 (73.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="71723" xml_f="71728" txt_i="39320" txt_f="39325"> Mild</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71761" xml_f="71770" txt_i="39326" txt_f="39335">64 (13.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71803" xml_f="71812" txt_i="39336" txt_f="39345">88 (18.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="71854" xml_f="71863" txt_i="39346" txt_f="39355"> Moderate</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71896" xml_f="71904" txt_i="39356" txt_f="39364">21 (4.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="71937" xml_f="71945" txt_i="39365" txt_f="39373">27 (5.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="71987" xml_f="71994" txt_i="39374" txt_f="39381"> Severe</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="72027" xml_f="72034" txt_i="39382" txt_f="39389">7 (1.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="72067" xml_f="72075" txt_i="39390" txt_f="39398">13 (2.7)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dew360tfn26"><p><sup><offsets xml_i="72147" xml_f="72148" txt_i="39399" txt_f="39400">*</offsets></sup><offsets xml_i="72154" xml_f="72344" txt_i="39400" txt_f="39590">Maximum severity of TEAEs experienced by each patient (no TEAE, mild, moderate and severe; this includes all TEAEs and not just those in the four System Organ Classes detailed in the table).</offsets></p></fn><fn id="dew360tfn27"><p><offsets xml_i="72377" xml_f="72399" txt_i="39591" txt_f="39613">Data are presented as </offsets><italic><offsets xml_i="72407" xml_f="72408" txt_i="39613" txt_f="39614">n</offsets></italic><offsets xml_i="72417" xml_f="72778" txt_i="39614" txt_f="39975"> (%). The four System Organ Classes most frequently associated with TEAEs during the stimulation and post-stimulation phases are presented. Reported values are for patients having experienced at least one TEAE during the stimulation and post-stimulation phases r-hFSH, recombinant human FSH; r-hLH, recombinant human LH; TEAE, treatment-emergent adverse event..</offsets></p></fn></table-wrap-foot></table-wrap></p><p><offsets xml_i="72825" xml_f="73823" txt_i="39977" txt_f="40972">The most common TEAEs during the stimulation and post-stimulation phases, reported in &gt;2% of either treatment group in the safety population, were headache (6.1% and 5.9% in the r-hFSH/r-hLH group and r-hFSH group, respectively), abdominal pain (2.4% and 2.5%), nausea (2.6% and 2.1%), spontaneous abortion (1.5% and 2.7%) and hot flush (2.2% and 0.8%). TEAEs of spontaneous abortion, abortion and missed abortion were reported for 13 patients treated with r-hFSH/r-hLH and 21 treated with r-hFSH. There were few serious TEAEs and the incidence was comparable between groups (1.7% and 3.6% with r-hFSH/r-hLH and r-hFSH, respectively). Serious TEAEs that occurred in more than one woman were missed abortion, which occurred in one woman treated with r-hFSH/r-hLH and three treated with r-hFSH, and abortion, which occurred in two women treated with r-hFSH. Ectopic pregnancy was reported for one patient receiving r-hFSH. There was no consistent pattern of TEAEs associated with either treatment.</offsets></p></sec></sec><sec sec-type="discussion" id="dew360s16"><title><offsets xml_i="73888" xml_f="73898" txt_i="40975" txt_f="40985">Discussion</offsets></title><p><offsets xml_i="73909" xml_f="74373" txt_i="40986" txt_f="41450">The ESPART study is the first adequately powered, randomized controlled trial to investigate reproductive outcomes in women with POR undergoing IVF/ICSI, using selection criteria that incorporate the Bologna criteria. With 939 subjects, it is the largest study ever performed in this category of patients. Indeed, it has previously been suggested that it might be unrealistic to expect randomized controlled trials investigating POR to achieve large sample sizes (</offsets><xref rid="dew360C26" ref-type="bibr"><offsets xml_i="74411" xml_f="74430" txt_i="41450" txt_f="41469">Papathanasiou, 2014</offsets></xref><offsets xml_i="74437" xml_f="74884" txt_i="41469" txt_f="41916">). There was no statistically significant difference in the number of oocytes retrieved following COS (primary outcome) between patients receiving r-hFSH/r-hLH and those receiving r-hFSH alone and, as expected, a low average number of oocytes was retrieved in both groups. This result is contrasted by recent data from a meta-analysis in patients with POR, in which significantly more oocytes were retrieved with r-hFSH/r-hLH versus r-hFSH alone (</offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="74922" xml_f="74929" txt_i="41916" txt_f="41923">Lehert </offsets><italic><offsets xml_i="74937" xml_f="74942" txt_i="41923" txt_f="41928">et al</offsets></italic><offsets xml_i="74951" xml_f="74958" txt_i="41928" txt_f="41935">., 2014</offsets></xref><offsets xml_i="74965" xml_f="75141" txt_i="41935" txt_f="42111">). However, this meta-analysis did not include patients with POR classified according to the Bologna criteria, instead including studies with heterogeneous definitions of POR (</offsets><xref rid="dew360C19" ref-type="bibr"><offsets xml_i="75179" xml_f="75186" txt_i="42111" txt_f="42118">Lehert </offsets><italic><offsets xml_i="75194" xml_f="75199" txt_i="42118" txt_f="42123">et al</offsets></italic><offsets xml_i="75208" xml_f="75215" txt_i="42123" txt_f="42130">., 2014</offsets></xref><offsets xml_i="75222" xml_f="75224" txt_i="42130" txt_f="42132">).</offsets></p><p><offsets xml_i="75231" xml_f="75950" txt_i="42133" txt_f="42849">The ESPART study did not include the complete ESHRE Bologna criteria, rather a stricter interpretation was applied to remove diagnostic subjectivity, reduce patient heterogeneity, and exclude patients with the worst reproductive prognosis. It included the objective parameters of age, an AMH level of 0.12–1.3 ng/ml and a previous ART cycle with ≤3 oocytes retrieved with a conventional stimulation protocol. Furthermore, the study randomized 939 patients stratified by age (&lt;35 or ≥35 years) and study site to ensure adequate statistical power to detect a difference between treatment groups for the primary endpoint, the number of oocytes retrieved, and provide uniform baseline characteristics between the groups.</offsets></p><p><offsets xml_i="75957" xml_f="76260" txt_i="42850" txt_f="43153">In the present study, the live birth rates were similar in both treatment groups (10.6% and 11.7% with r-hFSH/r-hLH and r-hFSH, respectively); interestingly, these rates were considerably higher than the live birth rates (5.5–7.4%) reported in retrospective analyses of Bologna poor ovarian responders (</offsets><xref rid="dew360C30" ref-type="bibr"><offsets xml_i="76298" xml_f="76306" txt_i="43153" txt_f="43161">Polyzos </offsets><italic><offsets xml_i="76314" xml_f="76319" txt_i="43161" txt_f="43166">et al</offsets></italic><offsets xml_i="76328" xml_f="76335" txt_i="43166" txt_f="43173">., 2014</offsets></xref><offsets xml_i="76342" xml_f="76344" txt_i="43173" txt_f="43175">; </offsets><xref rid="dew360C16" ref-type="bibr"><offsets xml_i="76382" xml_f="76391" txt_i="43175" txt_f="43184">La Marca </offsets><italic><offsets xml_i="76399" xml_f="76404" txt_i="43184" txt_f="43189">et al</offsets></italic><offsets xml_i="76413" xml_f="76420" txt_i="43189" txt_f="43196">., 2015</offsets></xref><offsets xml_i="76427" xml_f="76567" txt_i="43196" txt_f="43336">), and even lower live birth rates (2.6% per cycle) when only patients with POR undergoing natural cycle IVF were analysed retrospectively (</offsets><xref rid="dew360C28" ref-type="bibr"><offsets xml_i="76605" xml_f="76613" txt_i="43336" txt_f="43344">Polyzos </offsets><italic><offsets xml_i="76621" xml_f="76626" txt_i="43344" txt_f="43349">et al</offsets></italic><offsets xml_i="76635" xml_f="76642" txt_i="43349" txt_f="43356">., 2012</offsets></xref><offsets xml_i="76649" xml_f="76943" txt_i="43356" txt_f="43650">). This difference in live birth rate might be attributed to the ESPART study design as a randomized controlled trial with predefined inclusion criteria. Furthermore, it may reflect differences in the COS protocol used in ESPART compared with the studies included in the retrospective analyses.</offsets></p><p><offsets xml_i="76950" xml_f="77131" txt_i="43651" txt_f="43832">Although biochemical pregnancy rates differed between treatment groups, this difference diminished over the course of the pregnancy, with similar live birth rates in both groups. A </offsets><italic><offsets xml_i="77139" xml_f="77147" txt_i="43832" txt_f="43840">post hoc</offsets></italic><offsets xml_i="77156" xml_f="77628" txt_i="43840" txt_f="44312"> analysis to investigate this difference indicated that the incidence of total pregnancy outcome failure (combination of preclinical miscarriage, early or late spontaneous miscarriage and ectopic pregnancy) was lower in the r-hFSH/r-hLH group than in the r-hFSH group. This observation may relate to the potential beneficial effects of r-hLH supplementation on oocyte ‘quality’ and/or the capacity of r-hLH to support the pregnancy-sustaining function of the endometrium (</offsets><xref rid="dew360C33" ref-type="bibr"><offsets xml_i="77666" xml_f="77674" txt_i="44312" txt_f="44320">Tesarik </offsets><italic><offsets xml_i="77682" xml_f="77687" txt_i="44320" txt_f="44325">et al</offsets></italic><offsets xml_i="77696" xml_f="77703" txt_i="44325" txt_f="44332">., 2003</offsets></xref><offsets xml_i="77710" xml_f="77712" txt_i="44332" txt_f="44334">; </offsets><xref rid="dew360C6" ref-type="bibr"><offsets xml_i="77749" xml_f="77755" txt_i="44334" txt_f="44340">Bosch </offsets><italic><offsets xml_i="77763" xml_f="77768" txt_i="44340" txt_f="44345">et al</offsets></italic><offsets xml_i="77777" xml_f="77784" txt_i="44345" txt_f="44352">., 2011</offsets></xref><offsets xml_i="77791" xml_f="77860" txt_i="44352" txt_f="44421">). However, these findings should be confirmed in additional studies.</offsets></p><p><offsets xml_i="77867" xml_f="78017" txt_i="44422" txt_f="44572">LH supplementation may reduce the rate of granulosa/cumulus cell apoptosis (a marker of oocyte quality that is positively correlated with female age) </offsets><italic><offsets xml_i="78025" xml_f="78028" txt_i="44572" txt_f="44575">via</offsets></italic><offsets xml_i="78037" xml_f="78091" txt_i="44575" txt_f="44629"> increased epiregulin and amphiregulin up-regulation (</offsets><xref rid="dew360C18" ref-type="bibr"><offsets xml_i="78129" xml_f="78133" txt_i="44629" txt_f="44633">Lee </offsets><italic><offsets xml_i="78141" xml_f="78146" txt_i="44633" txt_f="44638">et al</offsets></italic><offsets xml_i="78155" xml_f="78162" txt_i="44638" txt_f="44645">., 2001</offsets></xref><offsets xml_i="78169" xml_f="78171" txt_i="44645" txt_f="44647">; </offsets><xref rid="dew360C5" ref-type="bibr"><offsets xml_i="78208" xml_f="78216" txt_i="44647" txt_f="44655">Bencomo </offsets><italic><offsets xml_i="78224" xml_f="78229" txt_i="44655" txt_f="44660">et al</offsets></italic><offsets xml_i="78238" xml_f="78245" txt_i="44660" txt_f="44667">., 2006</offsets></xref><offsets xml_i="78252" xml_f="78254" txt_i="44667" txt_f="44669">; </offsets><xref rid="dew360C32" ref-type="bibr"><offsets xml_i="78292" xml_f="78299" txt_i="44669" txt_f="44676">Ruvolo </offsets><italic><offsets xml_i="78307" xml_f="78312" txt_i="44676" txt_f="44681">et al</offsets></italic><offsets xml_i="78321" xml_f="78328" txt_i="44681" txt_f="44688">., 2007</offsets></xref><offsets xml_i="78335" xml_f="78337" txt_i="44688" txt_f="44690">; </offsets><xref rid="dew360C11" ref-type="bibr"><offsets xml_i="78375" xml_f="78396" txt_i="44690" txt_f="44711">Hill and Propst, 2012</offsets></xref><offsets xml_i="78403" xml_f="78565" txt_i="44711" txt_f="44873">). LH receptors are present in the endometrium during the window of implantation, playing an important role in embryo–endometrium cross-talk during implantation (</offsets><xref rid="dew360C2" ref-type="bibr"><offsets xml_i="78602" xml_f="78630" txt_i="44873" txt_f="44901">Banerjee and Fazleabas, 2010</offsets></xref><offsets xml_i="78637" xml_f="78639" txt_i="44901" txt_f="44903">, </offsets><xref rid="dew360C3" ref-type="bibr"><offsets xml_i="78676" xml_f="78680" txt_i="44903" txt_f="44907">2011</offsets></xref><offsets xml_i="78687" xml_f="78689" txt_i="44907" txt_f="44909">; </offsets><xref rid="dew360C11" ref-type="bibr"><offsets xml_i="78727" xml_f="78748" txt_i="44909" txt_f="44930">Hill and Propst, 2012</offsets></xref><offsets xml_i="78755" xml_f="79141" txt_i="44930" txt_f="45316">). Moreover, other indirect/direct effects of LH on endometrial function are poorly explored and require more research. The proposed positive effects of LH supplementation on both oocyte quality and endometrial receptivity might also explain significantly increased implantation rates previously observed in patients aged ≥35 years who received r-hLH supplementation to r-hFSH for COS (</offsets><xref rid="dew360C13" ref-type="bibr"><offsets xml_i="79179" xml_f="79188" txt_i="45316" txt_f="45325">Humaidan </offsets><italic><offsets xml_i="79196" xml_f="79201" txt_i="45325" txt_f="45330">et al</offsets></italic><offsets xml_i="79210" xml_f="79217" txt_i="45330" txt_f="45337">., 2004</offsets></xref><offsets xml_i="79224" xml_f="79226" txt_i="45337" txt_f="45339">; </offsets><xref rid="dew360C20" ref-type="bibr"><offsets xml_i="79264" xml_f="79270" txt_i="45339" txt_f="45345">Marrs </offsets><italic><offsets xml_i="79278" xml_f="79283" txt_i="45345" txt_f="45350">et al</offsets></italic><offsets xml_i="79292" xml_f="79299" txt_i="45350" txt_f="45357">., 2004</offsets></xref><offsets xml_i="79306" xml_f="79308" txt_i="45357" txt_f="45359">; </offsets><xref rid="dew360C4" ref-type="bibr"><offsets xml_i="79345" xml_f="79357" txt_i="45359" txt_f="45371">Barrenetxea </offsets><italic><offsets xml_i="79365" xml_f="79370" txt_i="45371" txt_f="45376">et al</offsets></italic><offsets xml_i="79379" xml_f="79386" txt_i="45376" txt_f="45383">., 2008</offsets></xref><offsets xml_i="79393" xml_f="79395" txt_i="45383" txt_f="45385">; </offsets><xref rid="dew360C21" ref-type="bibr"><offsets xml_i="79433" xml_f="79442" txt_i="45385" txt_f="45394">Matorras </offsets><italic><offsets xml_i="79450" xml_f="79455" txt_i="45394" txt_f="45399">et al</offsets></italic><offsets xml_i="79464" xml_f="79471" txt_i="45399" txt_f="45406">., 2009</offsets></xref><offsets xml_i="79478" xml_f="79480" txt_i="45406" txt_f="45408">; </offsets><xref rid="dew360C6" ref-type="bibr"><offsets xml_i="79517" xml_f="79523" txt_i="45408" txt_f="45414">Bosch </offsets><italic><offsets xml_i="79531" xml_f="79536" txt_i="45414" txt_f="45419">et al</offsets></italic><offsets xml_i="79545" xml_f="79552" txt_i="45419" txt_f="45426">., 2011</offsets></xref><offsets xml_i="79559" xml_f="79561" txt_i="45426" txt_f="45428">; </offsets><xref rid="dew360C10" ref-type="bibr"><offsets xml_i="79599" xml_f="79604" txt_i="45428" txt_f="45433">Hill </offsets><italic><offsets xml_i="79612" xml_f="79617" txt_i="45433" txt_f="45438">et al</offsets></italic><offsets xml_i="79626" xml_f="79633" txt_i="45438" txt_f="45445">., 2012</offsets></xref><offsets xml_i="79640" xml_f="79642" txt_i="45445" txt_f="45447">).</offsets></p><p><offsets xml_i="79649" xml_f="79926" txt_i="45448" txt_f="45725">Utilization of the Bologna POR criteria leads to a binary decision, (i.e. yes or no) as to whether or not a patient is a poor ovarian responder. However, it may be more useful to quantify the range of POR using ovarian response or reserve as an assessment tool. To this end, a </offsets><italic><offsets xml_i="79934" xml_f="79942" txt_i="45725" txt_f="45733">post hoc</offsets></italic><offsets xml_i="79951" xml_f="81092" txt_i="45733" txt_f="46871"> exploratory analysis based on the key POR inclusion criteria (age, AMH and previous ART outcome; the BSC analysis) permitted a more detailed investigation of the possible effect of treatment within three distinct subgroups defined according to baseline thresholds. Interestingly, using this concept of BSC and specifically considering live birth, outcomes differed between the treatment groups; r-hFSH/r-hLH showed more promise for the patients with moderate POR (BSC = 1) or severe POR (BSC = 2), and r-hFSH was associated with better outcomes for patients with mild POR (BSC = 0). The mild POR subgroup, representing one-third of the ESPART study population, included a heterogeneous group of patients who met the ESPART inclusion criteria but were younger than 40 years old, with either three or more oocytes in a previous ART cycle or an AMH level &gt;0.5 ng/ml in absence of a previous ART cycle. The analysis showed an interaction between BSC and treatment. However, these data need to be confirmed in additional studies stratifying patients with POR according to age, serum AMH and number of oocytes retrieved in previous ART cycles.</offsets></p><p><offsets xml_i="81099" xml_f="81726" txt_i="46872" txt_f="47499">In conclusion, the ESPART study represents pioneering work in POR and is the largest randomized, controlled study ever performed in women with POR. The study did not meet its primary endpoint of superiority of r-hFSH/r-hLH to r-hFSH in terms of number of oocytes retrieved following COS. Furthermore, the live birth rates per cycle were similar in both groups, but considerably higher than previously reported in retrospective studies that included Bologna POR patients, suggesting that recombinant gonadotropin stimulation protocols represent an effective treatment strategy in this challenging patient category. In addition, </offsets><italic><offsets xml_i="81734" xml_f="81742" txt_i="47499" txt_f="47507">post hoc</offsets></italic><offsets xml_i="81751" xml_f="82250" txt_i="47507" txt_f="48006"> analyses indicated that the incidence of total pregnancy outcome failure was significantly lower in the r-hFSH/r-hLH group than in the r-hFSH group and that live birth rate was associated with both treatment type (r-hFSH/r-hLH or r-hFSH) and POR baseline characteristics. Collectively, these data suggest that r-hFSH/r-hLH treatment may have added clinical value compared with r-hFSH alone in a subset of women with POR, but additional studies are needed to validate and confirm these observations.</offsets></p></sec><sec sec-type="supplementary-material" id="dew360s17"><title><offsets xml_i="82321" xml_f="82339" txt_i="48008" txt_f="48026">Supplementary data</offsets></title><p><offsets xml_i="82350" xml_f="82351" txt_i="48027" txt_f="48028">
</offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="82402" xml_f="82438" txt_i="48028" txt_f="48064">Supplementary data are available at </offsets><italic><offsets xml_i="82446" xml_f="82464" txt_i="48064" txt_f="48082">Human Reproduction</offsets></italic><offsets xml_i="82473" xml_f="82481" txt_i="48082" txt_f="48090"> online.</offsets></xref><offsets xml_i="82488" xml_f="82489" txt_i="48090" txt_f="48091">
</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="82545" xml_f="82567" txt_i="48093" txt_f="48115">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="sup1"><label><offsets xml_i="82642" xml_f="82663" txt_i="48116" txt_f="48137">Supplementary Table 1</offsets></label><media xlink:href="dew360suppl_table1.pdf"><caption><p><offsets xml_i="82726" xml_f="82762" txt_i="48137" txt_f="48173">Click here for additional data file.</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sup2"><label><offsets xml_i="82876" xml_f="82894" txt_i="48174" txt_f="48192">Supplementary Data</offsets></label><media xlink:href="dew360suppl_data.pdf"><caption><p><offsets xml_i="82955" xml_f="82991" txt_i="48192" txt_f="48228">Click here for additional data file.</offsets></p></caption></media></supplementary-material></sec></body><back><ack id="dew360ack1"><title>Acknowledgements</title><p>The authors would like to thank patients and their families, investigators, co-investigators and the study teams at each of the participating centres and at Merck KGaA, Darmstadt, Germany. Moreover, the authors would like to thank Prof. Philippe Lehert for his contributions to the interpretation of the study results, and Dr Robert Fisher for his contributions to the conception and design of the study. Medical writing assistance was provided by Alexander Jones, inScience Communications, London, UK, and funded by Merck KGaA, Darmstadt, Germany.</p><p>
<italic>ESPART Study Investigators</italic>: Belgium: Dr Candice Autin, Prof. Thomas D'Hooghe, Dr Wim Decleer, Prof. Michel Dubois, Prof. Herman Tournaye, Prof. Christine Wyns. Czech Republic: Dr Jaroslav Hulvert, Dr Tonko Mardesic, Dr Karel Rezabek, Dr Ales Sobek, Dr Petr Uher, Dr Hana Visnova. Denmark: Dr Jens Fedder, Dr John Kirk, Dr Anne Mikkelsen, Dr Anja Pinborg, Dr Sven Skouby. Estonia: Dr Aivar Ehrenberg, Dr Kai Haldre, Dr Tiina Loog. France: Prof. Claude Hocke, Dr Nathalie Massin, Dr Karine Morcel, Dr Géraldine Porçu-Buisson, Dr Catherine Rongieres. Germany: Prof. Hermann Behre, Dr Maren Goeckenjan-Festag, Prof. Georg Griesinger, Dr Thilo Schill, Dr Peter Sydow, Dr Andreas Tandler-Schneider, Prof. Bettina Toth. Hungary: Dr Peter Kovacs, Prof. Attila Torok. Italy: Prof. Vincenzo De Leo, Prof. Giuseppe De Placido, Dr Francesco Fusi, Prof. Giovanni Battista La Sala, Prof. Paolo Emanuele Levi Setti, Dr Enrico Papaleo, Dr Eleonora Porcu, Prof. Alberto Revelli, Dr Edgardo Somigliana. Latvia: Dr Maris Arajs, Dr Gints Treijs. Netherlands: Dr Bernard Cohlen. Poland: Dr Mariusz Kiecka, Dr Katarzyna Koziol, Prof. Waldemar Kuczynski, Prof. Rafal Kurzawa, Dr Michal Radwan, Dr Tomasz Rokicki, Prof. Slawomir Wolczynski. Spain: Dr Ernesto Bosch Aparicio, Dr Mario Lorenzo Brassesco Macazzaga, Dr Buenaventura Coroleu Lletget, Dr Javier Domingo, Dr Juan Jose Espinos-Gomez, Dr Manuel Fernandez Sanchez, Dr Marcos Ferrando Serrano, Dr Juan Antonio Garcia Velasco, Dr Jose Lorenzo Landeras Gutierrez, Dr Elkin Muñoz, Dr Manuel Muñoz Cantero, Dr Jose Maria Rubio Rubio, Dr Fernando Sanchez Martin, Dr Jose Serna Lopez, Dr Victoria Verdu Merino, Dr Augustin Ballesteros Boluda. Sweden: Dr Jan Olofsson, Dr Ann Thurin Kjellberg, Dr Göran Westlander. Turkey: Assoc. Prof. Abdullah Karaer, Prof. Bulent Berker, Prof. Cem Ficicioglu, Dr Emek Doger, Prof. Erol Tavmergen, Assoc. Prof. Gurkan Bozdag, Prof. Hikmet Hassa, Prof. Koray Elter, Prof. Onur Karabacak, Prof. Hakan Yarali. United Kingdom: Dr Garima Srivastava, Mr Akoub Khalef, Mr Geoffrey Trew, Mr Andrew Drakeley.</p></ack><sec id="dew360s19"><title>Authors’ roles</title><p>P.H., J.H. and J.S. participated in the conception and design of the study as well as the collection, analysis and interpretation of data. D.R., S.L., T.D.’H. and W.C. participated in the analysis and interpretation of the final data. All authors critically revised the current work for important intellectual content and gave final approval of the version of the publication to be published. All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of it are appropriately investigated and resolved.</p></sec><sec id="dew360s20"><title>Funding</title><p>Merck KGaA, Darmstadt, Germany.</p></sec><sec id="dew360s21"><title>Conflict of interest</title><p>P.H. has received honoraria for lectures and unrestricted research grants from Ferring, Merck KGaA and MSD. J.S., J.H. and W.C. are employees of EMD Serono Research and Development Institute, a business of Merck KGaA, Darmstadt, Germany. D.R. (current affiliation: Versartis, Inc., Menlo Park, CA, USA) is a former employee of EMD Serono Research and Development Institute, a business of Merck KGaA, Darmstadt, Germany. T.D.’H. and S.L. are employees of Merck KGaA, Darmstadt, Germany.</p></sec><ref-list><title>References</title><ref id="dew360C1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Alviggi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Andersen</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Buehler</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Conforti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Placido</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Esteves</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Galliano</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Polyzos</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Sunkara</surname><given-names>SK</given-names></name><etal>et al</etal></person-group>
<article-title>A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept</article-title>. <source>Fertil Steril</source><year>2016</year>;<volume>105</volume>:<fpage>1452</fpage>–<lpage>1453</lpage>.<pub-id pub-id-type="pmid">26921622</pub-id></mixed-citation></ref><ref id="dew360C2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Fazleabas</surname><given-names>AT</given-names></name></person-group>
<article-title>Endometrial responses to embryonic signals in the primate</article-title>. <source>Int J Dev Biol</source><year>2010</year>;<volume>54</volume>:<fpage>295</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="pmid">19876822</pub-id></mixed-citation></ref><ref id="dew360C3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Fazleabas</surname><given-names>AT</given-names></name></person-group>
<article-title>Extragonadal actions of chorionic gonadotropin</article-title>. <source>Rev Endocr Metab Disord</source><year>2011</year>;<volume>12</volume>:<fpage>323</fpage>–<lpage>332</lpage>.<pub-id pub-id-type="pmid">21845366</pub-id></mixed-citation></ref><ref id="dew360C4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Barrenetxea</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Agirregoikoa</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Jimenez</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>de Larruzea</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Ganzabal</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Carbonero</surname><given-names>K</given-names></name></person-group>
<article-title>Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles</article-title>. <source>Fertil Steril</source><year>2008</year>;<volume>89</volume>:<fpage>546</fpage>–<lpage>553</lpage>.<pub-id pub-id-type="pmid">17531989</pub-id></mixed-citation></ref><ref id="dew360C5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bencomo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Perez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Arteaga</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Acosta</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Pena</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Lopez</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Avila</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Palumbo</surname><given-names>A</given-names></name></person-group>
<article-title>Apoptosis of cultured granulosa-lutein cells is reduced by insulin-like growth factor I and may correlate with embryo fragmentation and pregnancy rate</article-title>. <source>Fertil Steril</source><year>2006</year>;<volume>85</volume>:<fpage>474</fpage>–<lpage>480</lpage>.<pub-id pub-id-type="pmid">16595230</pub-id></mixed-citation></ref><ref id="dew360C6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bosch</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Labarta</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Crespo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Simon</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Remohi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pellicer</surname><given-names>A</given-names></name></person-group>
<article-title>Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis</article-title>. <source>Fertil Steril</source><year>2011</year>;<volume>95</volume>:<fpage>1031</fpage>–<lpage>1036</lpage>.<pub-id pub-id-type="pmid">21067717</pub-id></mixed-citation></ref><ref id="dew360C7"><mixed-citation publication-type="other">
<person-group person-group-type="author"><collab>ESHRE</collab></person-group> ART fact sheet (July 2014). <year>2014</year>
<uri xlink:href="http://www.eshre.eu/Guidelines-and-Legal/ART-fact-sheet.aspx">http://www.eshre.eu/Guidelines-and-Legal/ART-fact-sheet.aspx</uri> (15 October 2015, date last accessed).</mixed-citation></ref><ref id="dew360C8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ferraretti</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Gianaroli</surname><given-names>L</given-names></name></person-group>
<article-title>The Bologna criteria for the definition of poor ovarian responders: is there a need for revision</article-title>. <source>Hum Reprod</source><year>2014</year>;<volume>29</volume>:<fpage>1842</fpage>–<lpage>1845</lpage>.<pub-id pub-id-type="pmid">25008235</pub-id></mixed-citation></ref><ref id="dew360C9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ferraretti</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>La Marca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fauser</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Tarlatzis</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nargund</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gianaroli</surname><given-names>L</given-names></name></person-group>
<article-title>ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria</article-title>. <source>Hum Reprod</source><year>2011</year>;<volume>26</volume>:<fpage>1616</fpage>–<lpage>1624</lpage>.<pub-id pub-id-type="pmid">21505041</pub-id></mixed-citation></ref><ref id="dew360C10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Levens</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Csokmay</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>DeCherney</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Whitcomb</surname><given-names>BW</given-names></name></person-group>
<article-title>The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis</article-title>. <source>Fertil Steril</source><year>2012</year>;<volume>97</volume>:<fpage>1108</fpage>–<lpage>1114</lpage>.<pub-id pub-id-type="pmid">22365075</pub-id></mixed-citation></ref><ref id="dew360C11"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Propst</surname><given-names>AM</given-names></name></person-group>
<chapter-title></chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Darwish</surname><given-names>AMM</given-names></name> (ed)</person-group>
<source>Enhancing Success of Assisted Reproduction</source>. <publisher-loc>Rijeka, Croatia</publisher-loc>: <publisher-name>InTechOpen</publisher-name>, <year>2012</year>, <fpage>53</fpage>–<lpage>76</lpage>.</mixed-citation></ref><ref id="dew360C12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hillier</surname><given-names>SG</given-names></name></person-group>
<article-title>Gonadotropic control of ovarian follicular growth and development</article-title>. <source>Mol Cell Endocrinol</source><year>2001</year>;<volume>179</volume>:<fpage>39</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">11420129</pub-id></mixed-citation></ref><ref id="dew360C13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Humaidan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bungum</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bungum</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Yding Andersen</surname><given-names>C</given-names></name></person-group>
<article-title>Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study</article-title>. <source>Reprod Biomed Online</source><year>2004</year>;<volume>8</volume>:<fpage>635</fpage>–<lpage>643</lpage>.<pub-id pub-id-type="pmid">15169576</pub-id></mixed-citation></ref><ref id="dew360C14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Humaidan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Schertz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>R</given-names></name></person-group>
<article-title>Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment</article-title>. <source>BMJ Open</source><year>2015</year>;<volume>5</volume>:<fpage>e008297</fpage>.</mixed-citation></ref><ref id="dew360C15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kocourkova</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Burcin</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kucera</surname><given-names>T</given-names></name></person-group>
<article-title>Demographic relevancy of increased use of assisted reproduction in European countries</article-title>. <source>Reprod Health</source><year>2014</year>;<volume>11</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">24885428</pub-id></mixed-citation></ref><ref id="dew360C16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>La Marca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Grisendi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Giulini</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sighinolfi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tirelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Argento</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Re</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tagliasacchi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Marsella</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sunkara</surname><given-names>SK</given-names></name></person-group>
<article-title>Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study</article-title>. <source>J Assist Reprod Genet</source><year>2015</year>;<volume>32</volume>:<fpage>931</fpage>–<lpage>937</lpage>.<pub-id pub-id-type="pmid">25925345</pub-id></mixed-citation></ref><ref id="dew360C17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>La Marca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sunkara</surname><given-names>SK</given-names></name></person-group>
<article-title>Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice</article-title>. <source>Hum Reprod Update</source><year>2014</year>;<volume>20</volume>:<fpage>124</fpage>–<lpage>140</lpage>.<pub-id pub-id-type="pmid">24077980</pub-id></mixed-citation></ref><ref id="dew360C18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Joo</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Na</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>OH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>WW</given-names></name></person-group>
<article-title>Cumulus cells apoptosis as an indicator to predict the quality of oocytes and the outcome of IVF-ET</article-title>. <source>J Assist Reprod Genet</source><year>2001</year>;<volume>18</volume>:<fpage>490</fpage>–<lpage>498</lpage>.<pub-id pub-id-type="pmid">11665664</pub-id></mixed-citation></ref><ref id="dew360C19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lehert</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kolibianakis</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Venetis</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Schertz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Saunders</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Arriagada</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Copt</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tarlatzis</surname><given-names>B</given-names></name></person-group>
<article-title>Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis</article-title>. <source>Reprod Biol Endocrinol</source><year>2014</year>;<volume>12</volume>:<fpage>17</fpage>.<pub-id pub-id-type="pmid">24555766</pub-id></mixed-citation></ref><ref id="dew360C20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Marrs</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Meldrum</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Muasher</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schoolcraft</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Werlin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>E</given-names></name></person-group>
<article-title>Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment</article-title>. <source>Reprod Biomed Online</source><year>2004</year>;<volume>8</volume>:<fpage>175</fpage>–<lpage>182</lpage>.<pub-id pub-id-type="pmid">14989794</pub-id></mixed-citation></ref><ref id="dew360C21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Matorras</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Prieto</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Exposito</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mendoza</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Crisol</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Herranz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Burgues</surname><given-names>S</given-names></name></person-group>
<article-title>Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study</article-title>. <source>Reprod Biomed Online</source><year>2009</year>;<volume>19</volume>:<fpage>879</fpage>–<lpage>887</lpage>.<pub-id pub-id-type="pmid">20031032</pub-id></mixed-citation></ref><ref id="dew360C22"><mixed-citation publication-type="other">
<person-group person-group-type="author"><collab>Merck</collab></person-group> GONAL-f 900 IU (66 mcg) pen. <year>2015</year>a. <uri xlink:href="https://www.medicines.org.uk/emc/medicine/14385">https://www.medicines.org.uk/emc/medicine/14385</uri> (30 March 2016, date last accessed).</mixed-citation></ref><ref id="dew360C23"><mixed-citation publication-type="other">
<person-group person-group-type="author"><collab>Merck</collab></person-group> SPC: Pergoveris 150 IU/75 IU powder and solvent for solution for injection. <year>2015</year>b. <uri xlink:href="https://www.medicines.org.uk/emc/medicine/20132">https://www.medicines.org.uk/emc/medicine/20132</uri> (1 June 2016, date last accessed).</mixed-citation></ref><ref id="dew360C24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Telfer</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>RA</given-names></name></person-group>
<article-title>The ageing ovary and uterus: new biological insights</article-title>. <source>Hum Reprod Update</source><year>2013</year>;<volume>19</volume>:<fpage>67</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">23103636</pub-id></mixed-citation></ref><ref id="dew360C25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Oudendijk</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Yarde</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Eijkemans</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Broekmans</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Broer</surname><given-names>SL</given-names></name></person-group>
<article-title>The poor responder in IVF: is the prognosis always poor?: a systematic review</article-title>. <source>Hum Reprod Update</source><year>2012</year>;<volume>18</volume>:<fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">21987525</pub-id></mixed-citation></ref><ref id="dew360C26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Papathanasiou</surname><given-names>A</given-names></name></person-group>
<article-title>Implementing the ESHRE ‘poor responder’ criteria in research studies: methodological implications</article-title>. <source>Hum Reprod</source><year>2014</year>;<volume>29</volume>:<fpage>1835</fpage>–<lpage>1838</lpage>.<pub-id pub-id-type="pmid">24916434</pub-id></mixed-citation></ref><ref id="dew360C27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Papathanasiou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Searle</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>King</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name></person-group>
<article-title>Trends in ‘poor responder’ research: lessons learned from RCTs in assisted conception</article-title>. <source>Hum Reprod Update</source><year>2016</year>. doi: <comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/humupd/dmw001">10.1093/humupd/dmw001</ext-link></comment>.</mixed-citation></ref><ref id="dew360C28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Polyzos</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Blockeel</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Verpoest</surname><given-names>W</given-names></name>, <name name-style="western"><surname>De Vos</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stoop</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Vloeberghs</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Camus</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Devroey</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tournaye</surname><given-names>H</given-names></name></person-group>
<article-title>Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria</article-title>. <source>Hum Reprod</source><year>2012</year>;<volume>27</volume>:<fpage>3481</fpage>–<lpage>3486</lpage>.<pub-id pub-id-type="pmid">22940767</pub-id></mixed-citation></ref><ref id="dew360C29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Polyzos</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Devroey</surname><given-names>P</given-names></name></person-group>
<article-title>A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel</article-title>. <source>Fertil Steril</source><year>2011</year>;<volume>96</volume>:<fpage>1058</fpage>–<lpage>1061 e1057</lpage>.<pub-id pub-id-type="pmid">22036048</pub-id></mixed-citation></ref><ref id="dew360C30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Polyzos</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Nwoye</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Corona</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Blockeel</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stoop</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Haentjens</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Camus</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tournaye</surname><given-names>H</given-names></name></person-group>
<article-title>Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI</article-title>. <source>Reprod Biomed Online</source><year>2014</year>;<volume>28</volume>:<fpage>469</fpage>–<lpage>474</lpage>.<pub-id pub-id-type="pmid">24581984</pub-id></mixed-citation></ref><ref id="dew360C31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Polyzos</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Sunkara</surname><given-names>SK</given-names></name></person-group>
<article-title>Sub-optimal responders following controlled ovarian stimulation: an overlooked group</article-title>. <source>Hum Reprod</source><year>2015</year>;<volume>30</volume>:<fpage>2005</fpage>–<lpage>2008</lpage>.<pub-id pub-id-type="pmid">26202582</pub-id></mixed-citation></ref><ref id="dew360C32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ruvolo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bosco</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pane</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Morici</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cittadini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Roccheri</surname><given-names>MC</given-names></name></person-group>
<article-title>Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures</article-title>. <source>Fertil Steril</source><year>2007</year>;<volume>87</volume>:<fpage>542</fpage>–<lpage>546</lpage>.<pub-id pub-id-type="pmid">17126339</pub-id></mixed-citation></ref><ref id="dew360C33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tesarik</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hazout</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mendoza</surname><given-names>C</given-names></name></person-group>
<article-title>Luteinizing hormone affects uterine receptivity independently of ovarian function</article-title>. <source>Reprod Biomed Online</source><year>2003</year>;<volume>7</volume>:<fpage>59</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">12930575</pub-id></mixed-citation></ref><ref id="dew360C34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>The ESHRE Capri Workshop Group</collab></person-group>
<article-title>Europe the continent with the lowest fertility</article-title>. <source>Hum Reprod Update</source><year>2010</year>;<volume>16</volume>:<fpage>590</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="pmid">20603286</pub-id></mixed-citation></ref><ref id="dew360C35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zegers-Hochschild</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Adamson</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>de Mouzon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ishihara</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Mansour</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nygren</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>van der Poel</surname><given-names>S</given-names></name></person-group>
<article-title>The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009</article-title>. <source>Hum Reprod</source><year>2009</year>;<volume>24</volume>:<fpage>2683</fpage>–<lpage>2687</lpage>.<pub-id pub-id-type="pmid">19801627</pub-id></mixed-citation></ref></ref-list></back></article>